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CHAPTER I 
 
INTRODUCTION 
 
A History of Antibiotics 
In the early 1940’s, antibiotics were introduced clinically for the treatment of bacterial 
infections.1-2  Antibiotics function by targeting essential physiological or metabolic functions of 
the bacterial cell, such as the biosynthesis of the cell wall, proteins, and DNA.1  Over the next 20 
years, more than 20 classes of antibiotics were discovered.  Each antibiotic class is distinguished 
by a shared common core structure or scaffold, but only four new classes have been introduced 
since the 1960s (Figure 1).2 Three of these classes, mutilins, lipopeptides, and oxazolidinones, are 
still currently in clinical trials.2  Therefore, they are not yet available for the clinical treatment of 
bacterial infection.  Furthermore, there is the possibility that these classes will not make it out of 
clinical trials for approval as a treatment by the FDA. 
Except for the discovery of the carbapenems class in 1985, the 40 year innovation gap in 
the identification of new classes of antibiotics was filled by developing synthetic modifications of 
existing antibiotic scaffolds.2  Furthermore, there has been a significant decrease in the number of 
new antibiotics approved by the FDA each year.4  The identification of new classes of antibiotics 
is a costly process and yields little profit for pharmaceutical companies, which explains the 
innovation gap in discovery.2, 4-5  Altogether, this is a cause for concern given the increasing 
problem of microbial antibiotic resistance.  
 
 2 
 
 
Microbial Antibiotic Resistance 
Shortly after the introduction of antibiotics to the clinical setting, evidence of microbial 
antibiotic resistance (MAR) emerged.  By the late 1950’s, resistance to multiple antibiotics was 
reported.2  MAR continues to spread rapidly and has become an increasing problem because of the 
dwindling availability of new antibiotic treatments.   
MAR is typically first caused through sequential mutations in chromosomes.  This is 
followed by resistance arising from mobile genetic elements, such as plasmids and bacteriophages.  
These mobile genetic elements can be transferred from one bacteria to another, but what is most 
concerning is that they can transfer across bacterial species.1   
There are three major mechanisms of resistance: (1) enzymatic inactivation of antibiotics 
through modification or destruction of the drug; (2) alteration of drug transportation; and (3) 
alteration of the intracellular drug target (Figure 2).1 Chromosomal mutations typically lead to 
 
Figure 1. Timeline of discovery of new classes of antibiotics with a 40 year innovation gap.2  
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alteration of the drug target and plasmid encoded proteins are responsible for the other two 
mechanisms of resistance.  
 
 
In 2013, the Center for Disease Control (CDC) released a report describing the rising 
antibiotic resistance threat in the United States.  According to this report, one of the major culprits 
for the rapid spread of MAR across the world are the over prescription and improper use of 
antibiotics.6  This includes the use of antibiotics in food-producing animals to prevent, control, and 
treat disease and promote growth, which contributes to MAR strains of bacteria in the food we eat.  
Additionally, the CDC states that almost 50% of administered antibiotics are unnecessary or 
ineffective as prescribed, resulting in an increase in MAR strains of healthy bacteria in the patient’s 
 
Figure 2. Mechanisms of microbial antibiotic resistance.1 The three major mechanisms of 
resistance are shown above.  This include alteration of the intracellular drug target, which is 
typically encoded by sequential chromosomal mutations.  Mechanisms of resistance that are 
typically transferred through mobile genetic elements, such as plasmids, include enzymatic 
inactivation of antibiotics through modification or destruction of the drug and alteration of drug 
transportation.  Reprinted with permission from Levy, S. B., and Marshall, B. (2004) 
Antibacterial resistance worldwide: causes, challenges and responses., Nat Med 10, S122-
129. Copyright 2004 Nature Publishing Group. 
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gut.6  Since plasmid encoded resistance can be passed between bacterial species, these two 
extraneous uses of antibiotics can increase the spread of MAR infections.   
The spread of MAR infections is reported to cause over 2 million illnesses and 23,000 
deaths per year in the United States.6  Combating MAR infections leads to prolonged treatment 
and extended hospitalization for patients.  This often results in increased healthcare costs and loss 
of productivity in society that is estimated to require up to 35 billion dollars per year.6   
Incremental improvements to existing classes of antibiotics has proven to be an effective 
short-term method to combat MAR infections.2  As MAR strains continue to spread, more long-
term strategies for treatment are needed.  The most promising strategies that have emerged are the 
discovery of new antibiotics and combination therapies.1-2, 4  Combinations of multiple antibiotics, 
including antibiotics no longer used for traditional treatments, have been used to successfully treat 
MAR infections.1-2, 4-5, 6-7  Furthermore, the combination of an antibiotic with an inhibitor to the 
enzymatic resistance mechanism for MAR infections has also been successful.  A notable example 
of this type of therapy is the drug Augmentin, which has been used to successfully treat infections 
resistant to penicillin.   This demonstrates the need for a clear understanding of the enzymatic 
resistance mechanisms for various antibiotics.  Knowledge of such mechanisms would allow for 
drug design of inhibitors to be used as part of combination therapies for MAR infections. 
 
Fosfomycin 
Fosfomycin (Fos), or cis-1,2-epoxy-propyl phosphonic acid, is a broad spectrum antibiotic 
isolated in 1969 from various strains of Streptomyces by Merck Research Laboratories.8  Fos is 
effective against both Gram-positive and Gram-negative bacteria.8  Fos inhibits cell wall 
biosynthesis by covalent inactivation of the enzyme pyruvate-uridine diphospho-N-
 5 
acetylglucosamine transferase (MurA).  Mur A catalyzes the ligation of a phosphoenolpyruvate to 
the 3’-hydroxyl group of UDP-N-acetylglucosamine (UDP-GlcNAc).9  The MurA reaction 
represents the first committed step in peptidoglycan synthesis, which is a necessary component for 
of the bacterial cell wall.  Fos is a phosphoenolpyruvate analogue that covalently binds to MurA 
at an active site cysteine residue (Cys115 in E. coli) in the presence of UDP-GlcNAc (Figure 3).10 
 
 
Fos is currently used in the United States under the trade name Monurol® and has low 
toxicity in humans.  It is typically prescribed in a single three gram oral dose for the treatment of 
urinary tract infections, but has also been used in the treatment of gastrointestinal infections and 
multi-drug resistant infections.11  Treatment with a large dose results in high concentrations of the 
active drug, which circumvents the primary MAR mechanism of alteration to drug transportation 
in cells.  Shortly after the discovery of Fos, resistance to the antibiotic was reported.  Chromosomal 
mutations leading to modification of the transportation of Fos and modification of MurA were the 
first types of resistance reported.12  Almost a decade later, plasmid encoded resistance to 
fosfomycin was observed after isolation of the transposon Tn2921 from Serratia marcescens.13  
 
Figure 3. Fos reaction mechanism.  Fos functions as a phosphoenolpyruvate analogue that can 
covalently bind to an active site cysteine residue (Cy115 in E. coli) of MurA when UDP-
GlcNAc is present. 
O
CH3P
-O
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O
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HO CH3
P
-O
OH
O S
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The gene Tn2921 was determined to encode a 16 kDa protein, FosA, which catalyzes the 
inactivation of fosfomycin by addition of glutathione (GSH).12, 14 
 
Fosfomycin Resistance Enzymes 
Based on sequence similarity and reactions catalyzed, there are three known classes of 
genomically encoded fosfomycin resistance enzymes:  FosA, FosX, and FosB (Figure 4).  FosA, 
found in Gram-negative organisms, is a manganese- and potassium-dependent GSH transferase.  
The enzyme catalyzes the nucleophilic addition of GSH to carbon-1 of Fos, which opens the 
epoxide ring producing a compound with no bactericidal properties.15  FosX is a manganese-
dependent epoxide hydrolase that catalyzes the hydration of Fos at carbon-1 resulting in inactive 
Fos.16  FosB, present in Gram-positive organisms, has been shown to catalyze a similar to the 
reaction to FosA.17  Since Gram-positive organisms do not contain GSH, a different low molecular 
weight (LMW) thiol is added to carbon-1 of Fos by FosB.  Figure 6 shows the reactions catalyzed 
by the three classes of Fos resistance enzymes. 
In addition to similarity in sequence and reactions catalyzed, the Fos resistance enzymes 
also share structural similarities.  These enzymes are members of the Vicinal Oxygen Chelate 
(VOC) superfamily that all contain a paired βαβββ motif (Figure 5).18  In Fos resistance enzymes 
this motif is found at the N-terminus of each subunit.  The enzymes exist as homodimers in which 
both monomers participate in coordination of the metal ion and formation of the enzyme active 
sites.3   
 7 
  
 
Figure 5. Ribbon representation of the structure of the Vicinal Oxygen Chelate superfamily’s 
βαβββ motif:  (A) view of the bleomycin resistance protein’s homodimer and (B) close-up view 
of the cavity formed by the paired βαβββ motifs. The side chains shown are at the positions 
occupied by the metal ligands of other VOC superfamily members. The representations were 
constructed with PDB 1BYL.3 Reprinted with permission from Armstrong, R. N. (2000) 
Mechanistic diversity in a metalloenzyme superfamily., Biochemistry 39, 13625-13632.. 
Copyright 2000 American Chemical Society. 
 
 
Figure 4. Sequence alignment of the three known classes of Fos resistance enzymes.  The 
sequence of FosA is from Pseudomonas aeruginosa, FosX is from Listeria monocytogenes, 
and FosB is from Staphylococcus aureus. 
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FosB 
FosB was initially described as a magnesium-dependent cysteine transferase.17  These early 
studies indicate that overexpression of FosB in Escherichia coli cells, confers high resistance to 
Fos with a minimum inhibitory concentration (MIC) > 20 mg/mL), similar to the overexpression 
of FosA (MIC > 30 mg/mL).17  Based on this similarity, it is expected that the catalytic efficiency 
of FosB with the appropriate thiol substrate and divalent metal activator would also be comparable 
to that of FosA activity with GSH, manganese, and potassium.  However, the in vitro catalytic 
activity of cysteine transferase function with magnesium as the metal activator is low (kcat/Km
thiol 
 
Figure 6. Reactions catalyzed by Fos resistance enzymes. FosA, a manganese- and potassium-
dependent GSH transferase, catalyzes the nucleophilic addition of GSH to carbon-1 of Fos 
opening the epoxide ring producing an inactive compound.  FosB, a divalent-dependent thiol-
transferases, catalyzes the nucleophilic addition of a LMW thiol, such as cysteine, to carbon-1 
of Fos producing an inactive compound similar to that created by FosA.  FosX is a manganese-
dependent epoxide hydrolase that catalyzes the hydration of Fos at carbon-1 resulting in 
inactive Fos.   
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= 180 ± 20 M-1s-1) compared to the manganese and potassium dependent FosA GSH transferase 
function (kcat/Km
thiol = 1.7 ± 0.3 X 105 M-1s-1).17  These data indicate that FosB may utilize a 
different thiol substrate and/or divalent metal activator for optimal FosB activity.   
At the time the work presented in this dissertation began, the structure of FosB was 
unknown.  The kinetic analyses presented here reveal the catalytic selectivity and mechanism of 
FosB activity.  Additionally, several high resolution crystal structures determined as a part of this 
work will be discussed to further support the kinetic data.  A better understanding of the catalytic 
mechanism, substrate selectivity, and structure of FosB could allow for the design of drugs used 
to inhibit FosB and increase the efficacy of Fos in the clinical setting. 
 
Bacillithiol 
 In 2009, bacillithiol (BSH) was isolated from Bacillus anthracis, Bacillus subtilis, and 
Deinococcus radiodurans (Figure 7).19  BSH is a LMW thiol found in Gram-positive organisms 
in concentrations similar to that of cysteine in these organisms.  The structure of BSH is similar to 
that of mycothiol (MSH), a LMW thiol that is found in mycobacteria and functions similarly to 
GSH.19-20  Incidentally, the biosynthetic pathway for BSH was discovered based on similarities 
with the MSH biosynthetic pathway. 20 
 
 
Figure 7. Structure of bacillithiol. 
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Bioinformatic analysis revealed a three step enzymatic process for the biosynthesis of BSH 
(Figure 8).  The enzyme BshA is a glycosyltransferase that catalyzes the formation of N-
acetylglucosamine malate (GlcNAc-Mal) using UDP-GlcNAc and L-malate, the first step in BSH 
biosynthesis.  BshB, a deacetylase, hydrolyzes the acetyl group from GlcNAc-Mal to generate the 
second intermediate, glucosamine-malate (GlcN-Mal).  The final step is the addition of cysteine 
to form BSH and is proposed to be catalyzed by BshC, a putative cysteine ligase. 
 
 
The enzymatic activities of BshA and BshB have been confirmed in vitro, but confirmation 
of in vitro BshC activity still remains elusive.20  However, HPLC analysis of BshC null mutant 
strains revealed a complete absence of BSH leading to a 5-fold increase in the accumulation of 
 
Figure 8. Proposed biosynthesis pathway for BSH.  The glycosyltransferase, BshA, catalyzes 
the first step in BSH biosynthesis, which is the formation of GlcNAc-Mal using UDP-GlcNAc 
and L-malate.  BshB, a deacetylase, hydrolyzes the acetyl group from GlcNAc-Mal to generate 
the second intermediate, GlcN-Mal.  The final step is the addition of cysteine to form BSH and 
is proposed to be catalyzed by BshC, a putative cysteine ligase.  
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GlcN-mal compared to wild type strains.20  This indicates BshC is the likely candidate to catalyze 
the final step of BSH biosynthesis.  
 A study of BSH activity in wild type strains compared to BSH null mutant strains revealed 
reduced sporulation efficiency and an increased sensitivity to high salt, acid stress, thiol alkylating 
agents, thiol-reactive electrophiles, and Fos in cells lacking BSH (Table 1).20  This suggests BSH, 
like GSH and MSH, plays a role in detoxification of electrophiles and antibiotics. 
 
 
Results from Newton and Fahey revealed the presence of a BSH-dependent cellular 
detoxification system that is analogous to the MSH- and GSH-dependent detoxification systems.21  
BSH-dependent clearance of toxins begins by cleaving the amide bond linking GlcN-Mal to 
cysteine in BS-toxin conjugates.  The resulting GlcN-Mal is recycled to reform BSH and the 
cysteine-toxin conjugate is acetylated to form a mercapturic acid, which is exported out of the cell.  
The activity of this system was confirmed using monobromobimane, monochlorobimane, and 
Table 1. Phenotypes of BSH null cells 
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rifamycin detoxification assays, confirming the role of BSH in cellular detoxification of 
electrophiles and antibiotics.21 
The comparison of wild type strains to BSH null mutant strains also revealed an increase 
in sensitivity to Fos (Table 1).20  Additionally, Sharma et al. completed a chemical synthesis of 
BSH and reported initial time course data comparing FosB L-cysteine transferase activity and BSH 
transferase activity (Figure 9).22  Together these results indicate that BSH is the preferred LMW 
thiol substrate for FosB.   Work presented in this dissertation will reveal that FosB is a manganese-
dependent BSH-transferase. 
 
 
  
 
Figure 9. Time course kinetic analysis of FosB catalyzed addition of () 1 mM BSH or () 
1 mM L-Cys to fosfomycin.  Reactions were carried in 20 mM HEPES, pH 7.0 with 2 mM 
fosfomycin, 1 mM MgCl2, and 0.5 µM FosB from S. aureus. Reprinted with permission from 
Sharma, S. V.; Jothivasan, V. K.; Newton, G. L.; Upton, H.; Wakabayashi, J. I.; Kane, M. G.; 
Roberts, A. A.; Rawat, M.; La Clair, J. J.; Hamilton, C. J., Chemical and Chemoenzymatic 
syntheses of bacillithiol: a unique low-molecular-weight thiol amongst low G + C Gram-
positive bacteria. Angew Chem Int Ed Engl 2011, 50 (31), 7101-4. Copyright 2011 
JOHN/WILEY & SONS, INC. 
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Methods for Determining Protein Structure 
The determination of a protein’s three-dimensional structure can provide insight into the 
protein’s function and mechanism of action.  Two techniques commonly employed in the 
determination of protein structure include nuclear magnetic resonance (NMR) spectroscopy and 
X-ray crystallography.  Both methods are well-recognized techniques to provide high-resolution 
structural determination of proteins, protein-protein interactions, and protein-ligand interactions.23  
However, both methods suffer from obstacles that hinder their utility for investigating structural 
dynamics of proteins and their interactions.  A major challenge in X-ray crystallography is that 
analyses can only be made in the non-native solid-state, making it difficult to elucidate dynamic 
movement and interactions in proteins.24  NMR spectroscopy is solution based and can provide 
structural dynamic information, but it requires high concentrations of sample and is only suitable 
for certain proteins.25  Backbone amide Hydrogen/Deuterium exchange mass spectrometry (HDX-
MS) has emerged as a complementary technique to X-ray crystallography and NMR spectroscopy 
to study protein structure and dynamics.   
 
X-ray Crystallography 
 X-ray crystallography requires the protein to be arranged into a uniform pattern forming a 
crystal lattice.26 Once the protein crystal is large enough, it can then be analyzed by a high-
resolution X-ray diffraction experiment.  When the crystal is exposed to incident X-rays of known 
wavelength, a diffraction pattern is obtained.  This diffraction pattern can be used to determine a 
three-dimensional picture of the electron density for the crystal.  The electron density reveals the 
position of atoms in the crystals and ultimately the three-dimensional structure of the protein can 
be determined.26 
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 There are a variety of limitations to this technique.  The first hurdle is obtaining a large, 
uniform crystal.  Finding the best diffracting, uniform crystal requires screening of multiple crystal 
conditions with a variety of changes, such as precipitants, buffers, pH ranges, and protein 
concentrations.26  This process of screening typically requires a large amount of soluble protein, 
which can be problematic for certain proteins.  Additionally X-rays can cause significant damage 
to the crystals during data collection, which can be minimized by flash-freezing the crystal before 
exposure to the X-rays.26  However, this requires a cryo-protectant that will not damage the crystal 
and will not interfere with the diffraction. 
 Once a suitable diffraction data set is collected, the phases must be determined.  Since the 
phase cannot be directly extracted from the data set, they must be analyzed using another method.26  
One method uses molecular replacement with a related protein structure if such a structure is 
available.26  If no related structure is available, then multi-wavelength anomalous dispersion can 
be utilized.26  This requires the presence of a heavy atom, such as selenium, which can be 
incorporated during protein expression and purification.   
 Finally, the structure determined from X-ray crystallography is for one possible state of the 
protein.  The crystal freezes the protein into a static structure, which allows the diffraction pattern 
to be uniform.  The addition of substrates, products, and co-factors with the sample during 
crystallization can result in different protein states.  While multiple structures can indicate dynamic 
changes are occurring, this technique cannot be used to investigate active dynamic movement of 
protein.   
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Nuclear Magnetic Resonance Spectroscopy 
     NMR relies upon analysis of a spinning nucleus with magnetic properties in an 
applied magnetic field.  Analysis of 1H, 2H, 13C, and 15N nuclei with a variety of experiments is 
used when determining protein dynamics and atomic-resolution structure by NMR.27  The dynamic 
information is determined from relaxation of nuclei after excitation.27  For these experiments, 
protein must be labeled with 2H, 13C, and 15N.  This is often costly and can decrease the amount of 
protein obtained during expression and purification.  Furthermore, the protein must be soluble for 
the experiments, which can be a barrier for certain proteins. 
 
Hydrogen/Deuterium Exchange Mass Spectrometry Theory and Methodology 
HDX-MS is a sensitive method used to study protein interactions with ligands and other 
proteins.  It has numerous advantages including no protein size limitations and sub-micromolar 
range for protein concentration.  Hydrogen/Deuterium exchange was first described in the 1950s 
by Kaj Ulrik Linderstrøm-Lang when he calculated the extent of deuteration of D2O-stabilized 
proteins via density gradient tubes.28  In 1993, the study of horse cytochrome c incubated in D2O 
as a function of time, proteolyzed by pepsin, and analyzed using fast atom bombardment mass 
spectrometry (MS) was the first example of HDX-MS.29  In 1994, HDX-MS was completed 
utilizing electrospray ionization (ESI) MS coupled to liquid chromatography to complete the first 
structural dynamic studies of a whole protein in solution.30 
While hydrogen exchange can be both acid- and based- catalyzed reactions, at 
physiological pH the reaction is typically base-catalyzed.31  In a base-catalyzed exchange, the 
amide nitrogen proton is first abstracted by hydroxide ion and subsequently protonated by a solvent 
proton.  HDX kinetics are effected by factors including pH, polypeptide conformation, solvent 
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exposure, and structural dynamics that alter the chemical environment of reactive sites on the 
protein.32  Rapid kinetics, having an intrinsic exchange rate of about 10 s-1, is indicative of solvent 
exposure, while slow kinetics indicate either solvent protection or possible hydrogen bonding 
(Figure 10).33  The exchange of hydrogen for deuterium on the amide backbone is dependent upon 
the rate of structure unfolding (ko) and refolding (kc), which is mediated by structural fluctuations 
that disrupt the hydrogen bonds and result in temporary solvent access.  Therefore, measuring the 
rate of deuterium incorporation as a function of time provides information on protein conformation 
and conformational changes due to structural perturbations. 
 
 
HDX-MS relies on the base-catalyzed mechanism occurring at neutral pH, with the most 
common analysis techniques involving continuous labeling (Figure 11).34  In this method, purified 
protein in a buffered solution made with H2O is diluted in deuterated solvent and incubated at 
room temperature and neutral pH over a series of time points ranging from seconds to hours or 
days.  The exchange is quenched by acidification to pH 2.5 through dilution with ice-cold buffer 
in H2O, decreasing the temperature to 0 °C.  The quench reduces HDX on the backbone amides 
 
Figure 10. The Linderstrøm-Lang model of HDX.  Amide protons that are solvent exposed 
exchange with deuterons in the solvent with a half-life on the order of milliseconds.  Amide 
protons that are buried in the structure or involved in hydrogen bonding exchange with a half-
life on the order of seconds to years and are dependent upon the rate of structure unfolding (ko) 
and refolding (kc).  This allows kinetic analysis of HDX to reveal aspects of structural 
conformation and conformational dynamics. 
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by 105, but other exchangeable groups will exhibit rapid back exchange.35  Therefore, the 
exchanged deuteriums are trapped and label only the backbone amides.  The sample is digested by 
an acidic protease, such as pepsin, and analyzed by reverse-phase liquid chromatography coupled 
to ESI-MS in positive mode.  The MS data is analyzed for the change of m/z (mass to charge ratio) 
for individual peptides over time.  Due to the relative lack of cleavage specificity of pepsin, all 
analyzed peptides are sequenced by tandem mass spectrometry (MS/MS) prior to HDX-MS 
analyses. 
 
 
Figure 11. HDX- MS experimental method.  (A) Incubation of a protein in deuterated solvent 
results in the incorporation, or in-exchange, of deuterium at multiple sites.  Quenching the 
incorporation and diluting the protein in solvent lacking deuterium results in the loss, or back-
exchange, of deuterium at all sites except for those of backbone amide nitrogens.  This results 
in deuterium labeling exclusive to the backbone of the protein and can be utilized to make 
structural analyses.  (B) The HDX assay involves a range of D2O incubation times followed 
by quenching and proteolysis.  Each resulting peptide is subsequently analyzed for deuterium 
incorporation as a function of time by LC-MS.   
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For each time point, the number of deuterons incorporated onto the backbone amide 
nitrogens of each peptide is calculated from the MS data using the centroid of the resulting isotopic 
envelope (Figure 12).  The number of incorporated deuterons is plotted as a function of time and 
fit to a sum of first-order exponential rate terms.  HDX kinetic rates are generally divided into 
three phases including fast, intermediate, and slow.  These three phases of exchange can be utilized 
to analyze structural perturbations of a protein as a result of experimental conditions that cause 
conformational changes.   
 
 
 
Figure 12. HDX kinetic analyses.  (A) Incorporation of deuterium for each peptide is observed 
in a series of mass spectra as an increase in m/z (mass to charge ratio), which can be used to 
determine the average mass.  (B) The number of deuterons incorporated onto each peptide is 
plotted as a function of time and fit to a sum of first order exponential rate terms.  Perturbation 
of protein structure results in significant changes in HDX kinetics, illustrated by the red and 
black traces representing two different experimental conditions.  These kinetic changes are 
used to make conformational determinations. 
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Purpose of These Studies 
 Multi-drug resistant bacterial infections have emerged as a serious global health threat 
according to both the CDC and World Health Organization.6  Developing novel treatments to 
combat these serious diseases is necessary to fight the outbreak of infections.  One method of 
treatment currently used combines multiple antibiotics to combat these infections and it has been 
suggested to include the use of older antibiotics, such as Fos.1-2, 5a, 7  Additionally, the combination 
of antibiotics with inhibitors to combat resistance have proven effective as a treatment.  The 
purpose of this study is to utilize kinetic analyses and structural studies to determine the catalytic 
mechanism and substrate selectivity of FosB.  As FosB confers enzymatic resistance to Fos in 
Gram-positive organisms, furthering the understanding of the function of FosB will aid in the 
discovery of possible FosB inhibitors to increase the efficacy of Fos in the clinical setting. 
 At the initiation of this project, FosB was believed to be a magnesium-dependent cysteine-
transferase, but the discovery of a new LMW thiol, BSH, led to the suggestion that BSH might be 
a better thiol substrate for FosB.19-20, 22  Additionally, there were no known crystal structures of 
FosB.  It is the aim of this study to determine the in vitro substrate selectivity of FosB and to 
investigate divalent metal activation of FosB BSH-transferase activity.  We also set out to 
determine the crystal structure of FosB in an effort to determine the catalytic mechanism.  Based 
on multiple crystal structures determined during this project, we initiated HDX-MS analysis to 
evaluate the structural dynamics of FosB upon Fos binding.  
The biosynthetic pathway for BSH has been reported, but the final step has yet to be 
confirmed in vitro.20  Preliminary results indicate that the final step is catalyzed by the enzyme 
BshC, a putative cysteine ligase.20  Understanding the full biosynthetic pathway of BSH could 
provide an even more cost effective method of producing BSH, which would be beneficial for 
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studying FosB activity.  This information could also provide an additional pathway as a target for 
FosB inhibition in vivo.  In conjunction with Dr. Paul Cook’s lab at Grand Valley State University, 
this research also worked to determine the substrate identity of BshC as a complement to 
investigating FosB activity.    
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
 Buffer salts were purchased from Research Products International Corporation.  All 
crystallization materials were from Hampton Research.  Metals were obtained as their chloride 
salts from J.T. Baker.  L-cysteine was purchased from Sigma Life Sciences.  Fosfomycin disodium 
salt was from MP Biomedicals, LLC.  BSH was synthesized as BSSB by the Vanderbilt Institute 
of Chemical Biology Chemical Synthesis Core. pET28 (FosBSa) was from Platinum PCR 
Supermix and custom primers were ordered from Invitrogen (Carlsbad, CA). Restriction enzymes 
were from New England Biolabs (Ipswich, MA).  The pET20b(+) vector was from EMB 
Chemicals, Inc. (Gibbstown, NJ).  XL1-blue supercompetent cells and BL21-Gold (DE3) cells 
were from Agilent Technologies (Santa Clara, CA). 
 
Methods 
Cloning and Expression of FosB Enzymes for Kinetic Analyses 
FosBBs. The fosB gene from Bacillus subtilis was cloned and the FosBBs enzyme expressed 
and purified as previously described.16 
 
FosBSa and FosBBc. The fosB gene from Staphylococcus aureus was amplified from 
genomic DNA as previously described.19 The fosB gene from Bacillus cereus was amplified from 
genomic DNA obtained from the ATCC (10987). Each gene was subcloned into the pTYB12 
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vector with an N-terminal intein tag (New England Biolabs).  BL21(DE3) E. coli competent cells 
were transformed with the expression vector and cultured in 1 L of Terrific Broth in 2.8 L Fernbach 
flasks with baffles at 37 °C and 200 rpm in a New Brunswick Innova incubator shaker.  When an 
OD600 of 0.5 - 0.8 was reached, the culture was cooled to 18 °C and expression was induced by the 
addition of 0.1 mM IPTG.  The cells were further cultured at 18 °C and 200 rpm for 24-30 hours. 
Cells were harvested by centrifugation at 6500 x g and 4 °C for 10 min and stored at -20 °C.  
Frozen cell pellets were resuspended in cold Intein Buffer (20 mM HEPES (pH 8.0) containing 1 
mM EDTA, 500 mM NaCl) and 2 Complete Mini Protease Cocktail Inhibitor tablets (Roche 
Diagnostics).  Lysozyme (0.2 mg/mL) was added and the mixture was stirred at 4 °C for 30 min.  
Cells were further lysed by sonication (50% power, 60% duty cycle, and 2 min on, 3 min off) on 
ice, until they were no longer viscous.  Cellular debris was cleared by centrifugation at 30000 x g 
and 4 °C for 30 min. 
The cleared lysate was added to a 25 mL Chitin resin (New England Biolabs) gravity 
column equilibrated with Intein Buffer and washed with additional Intein Buffer.  Intein Buffer 
containing 50 mM cysteine was added to the column and incubated at room temperature for 48 
hours.  FosB was eluted with Intein Buffer, concentrated to ~10-15 mL, and dialyzed (molecular 
mass cutoff of 6-8000 kDa) against 4 L of 20 mM HEPES containing 50 mM NaCl, 1 mM EDTA 
and 6 g Chelex Resin (pH 7.5)] at 4 °C overnight.  The final sample was concentrated in an Amicon 
ultrafiltration system (molecular mass cutoff of 10000 kDa) to ~0.5 mM. 
 
FosBBa. The fosB gene from B. anthracis was synthesized based on the known sequence as 
follows.  Custom oligonucleotides were purchased from Sigma (St. Louis, MO) and purified via 
standard desalting.  The PCR Supermix was purchased from Invitrogen (Carlsbad, CA).  The 
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pGEM kit was purchased from Promega (Madison, WI).  Restriction endonucleases were 
purchased from New England Biolabs (Ipswitch, MA).  Gel extraction and miniprep kits were 
purchased from Qiagen (Venlo, Netherlands).  XL1-blue chemically competent E. coli were 
purchased from the Molecular Cell Biology Resource Core at the Vanderbilt University Medical 
Center. 
Gene synthesis was carried out using methods similar to those used by Bernat et al.12  The 
FosB gene sequence was divided into eight sense/antisense alternating oligonucleotides (labeled 
sequentially as A-H) of about 70 bp with approximately 18 bp of overlapping, complementary 
sequence (Table 2).  Oligonucleotide A incorporates a 5’ Nde I site and oligonucleotide H 
incorporates a 3’ Xho I site. 
 
 
Four polymerase chain reactions (PCR) (labeled as 1-4) were set up using PCR Supermix 
(10 µL total each reaction).  The reactions contained the mixture of oligonucleotides (750 nM 
each) indicated in Table 2.  The reactions were cycled in accordance with the manufacturer’s 
thermocycling parameters for 3 cycles.  5 µL from these reactions were combined to make 
reactions 5 and 6 as indicated in Table 2.  Reactions 5 and 6 were then cycled for 3 cycles.  5 µL 
of reactions 5 and 6 were combined to make reaction 7, which was cycled for 3 cycles.  Finally, 
Table 2. Oligonucleotides for FosBBa gene synthesis 
Oligo Sequence (5’-3’) Reaction 
A gggggggcatatgttaaaaggaatcaatcatctttgtttttcagtatctaatttagaagattctattacattt 1 5 7 
B atgcaagttttcttcctctaactaataattctccttccaatactttttcgtaaaatgtaatagaatcttc 
C gaggaagaaaacttgcatattttaatatatgtggagtatggatagcgcttaatgaagaaatacatattccaa 2 
D tctgttcaacagaaaacgcaatatgtgtataagattgatgaatctcttttcttggaatatgtatttcttc 
E gcgttttctgttgaacagaaagactttgaacgtctactgcagcgattagaagaaaacgatgttcatattt 3 5 
F caacaaaatatatagattcacaatcccttacatcccgttctcttccttgtaaaatatgaacatcgttttc 
G gaatctatatattttgttgatccagacgggcataagtttgaatttcattcagggacattgcaagaaaggc 4 
H ttttttctcgagttagtaaaacgtcatatgaggtttatcttccctatagtaattaagcctttcttgcaatgtcc 
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the FosB gene was PCR-amplified from reaction 7 with oligonucleotides A and H using the PCR 
Supermix. 
The final PCR reaction was run on a 1.6% agarose gel, and a band of approximately 420 
bp was excised from the gel.  The DNA was extracted, A-tailed, and ligated into the pGEM-T 
vector.  The resulting plasmid was used to transform XL1-blue chemically competent cells, which 
were plated onto LB/agar/amp/IPTG/Xgal plates for blue/white screening.  White colonies were 
selected for growth in LB media, and plasmids were extracted.  The plasmids were digested with 
Nde I and Xho I and analyzed via gel electrophoresis.  Plasmids containing a gene of the 
appropriate size were sequenced at the Vanderbilt DNA Sequencing Core Facility.  The FosB gene 
from a pGEM-FosB clone with the appropriate sequence was digested with NdeI and XhoI and 
ligated into expression vectors.  
The synthetic gene was then subcloned into a pET-28b vector (Novagen) with an N-
terminal hexahistadine tag.  BL21(DE3) E. coli competent cells were transformed with the 
expression vector and cultured in Terrific Broth as described above at 37 °C and 200 rpm.  When 
an OD600 of between 0.5 and 0.8 was reached, the culture was cooled to 20 °C and expression was 
induced by the addition of 0.1 mM IPTG.  The cells were further cultured at 20 °C and 200 rpm 
for 15-20 hours.  Cells were harvested by centrifugation at 6500 x g and 4 °C for 10 min and stored 
at -20 °C.  Frozen cell pellets were resuspended in cold Lysis Buffer (20 mM HEPES, pH8.0; 300 
mM NaCl; 10 mM Imidazole) with 2 protease inhibitor tablets.  Lysozyme (0.2 mg/mL) was added 
and the mixture was stirred at 4 °C for 1 hour.  Cells were further lysed by sonication (50% power, 
60% duty cycle, and 2 min on, 3 min off) on ice, until they were no longer viscous.  Cellular debris 
was cleared by centrifugation at 30000 x g and 4 °C for 30 min. 
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The cleared lysate was added to a 5 mL Ni-NTA agarose (Qiagen) equilibrated with Lysis 
Buffer and incubated by inversion at 4 °C for 1 hour.  Resin was applied to a gravity column and 
washed with 10 column volumes of Lysis Buffer.  FosB was eluted with a similar buffer, 
containing 300 mM Imidazole, concentrated to ~10-15 mL, and dialyzed (molecular mass cutoff 
of 6-8000 kDa) against 4L cold buffer (20 mM HEPES, pH 7.5; 50 mM NaCl; 1 mM EDTA; 6 g 
Chelex Resin) at 4 °C overnight.  The final sample was concentrated in an Amicon ultrafiltration 
system (molecular mass cutoff of 10000 kDa) to ~1 mM. 
 
Preparation BSH for Enzyme Assays.  
Approximately 30 mg bacillithiol disulfide (BSSB) was dissolved in 50 µL 20 mM HEPES, 
pH 7.0.  This was adjusted to a pH of 7.0 by addition of 1 M HEPES (pH 7.0) to final volume of 
~1 mL.  The BSSB sample was loaded onto a Reduce-ImmTM Immobilized Reductant Column 
(Pierce) equilibrated with Buffer #1 (100 mM HEPES (pH 8.0) containing 1 mM EDTA) and 
activated per the manufacturer’s directions.  After incubation at room temperature for 30-60 min, 
bacillithiol (BSH) was eluted with 9 mL of Buffer #1 and collected in 1 mL fractions.  The [thiol] 
in the fractions was determined using the DTNB assay. 
 
Continuous 31P-NMR Activity Assays of FosBSa, FosBBa, FosBBc, FosBBs with Mg2+ or Ni2+.  
FosB (0.5 µM) was equilibrated for 5 minutes with either 1 mM MgCl2 or 10 µM NiCl2 
and 4 mM Fos in 20 mM HEPES (pH 7.0).  The reaction was initiated by addition of 2 mM BSH 
or cysteine, transferred to an NMR tube, and allowed to react at room temperature.  At various 
time points a 31P with 1H decoupling NMR spectra was collected using Bruker DRX-500 MHz 
NMR.  Cys-Fos, BS-Fos, and Fos had 31P chemical shifts of 18.8, 18.5, and 11.9 ppm, respectively. 
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Using the law of conservation of mass, the substrate and product peak heights were measured and 
the amount of product formed was calculated from the ratio between the peak heights and the total 
concentration of fosfomycin used in the reaction. 
 
Continuous 31P-NMR Activity Assays of FosBBc with Zn2+.  
Intein-tagged FosBBc (0.5 µM) was equilibrated for 5 min with 100 µM ZnCl2 and 8 mM 
Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated by addition of 4 mM BSH or L-cysteine, 
transferred to an NMR tube, and allowed to react at 298 K.  At various time points, a 31P with 1H 
decoupling NMR spectrum was collected using Bruker AV-400 MHz NMR.  Analysis of the data 
was completed according to the method previously described for activity assays with Mg2+ or Ni2+. 
 
Continuous 31P-NMR Activity Assays of FosBBc with Ni2+and Mg2+  
Intein-tagged FosBBc (0.25 µM) was equilibrated for 5 min with either 1 mM MgCl2 or 10 
µM Ni Cl2 and 4 mM Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated by addition of 2 
mM BSH or L-cysteine, transferred to an NMR tube, and allowed to react at 298 K.  At various 
time points, a 31P with 1H decoupling NMR spectrum was collected using Bruker DRX-500 MHz 
NMR.  Analysis of the data was completed according to the method previously described for 
activity assays with Mg2+ or Ni2+. 
 
End Point31P-NMR Activity Assays of FosBBc with Mn2+  
Intein-tagged FosBBc (0.25 µM) was equilibrated for 5 min with 10 µM MnCl2 and 4 mM 
Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated by addition of 2 mM BSH or L-cysteine 
and allowed to react at 298 K.  Since Mn2+ can interfere with the NMR analysis, the reactions 
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were quenched at various time points by vortexing with 20 µL of chloroform followed by freezing 
on dry ice for 10 minutes.  After thawing and centrifugation, the aqueous layer was incubated with 
chelex resin for 1 hour to remove any metals.  The resin was removed via centrifugation and the 
supernatant was transferred to an NMR tube to collect a 31P with 1H decoupling NMR spectrum 
for each time point using Bruker DRX-500 MHz NMR.  Analysis of the data was completed 
according to the method previously described for activity assays with Mg2+ or Ni2+. 
 
Steady State Kinetic Assays of FosBBc with Mn2+ 
Mn2+-dependent inactivation of Fos by FosBBc was measured for both BSH transferase and 
L-cysteine transferase activity.  Intein-tagged FosBBc (0.25 µM) was equilibrated for 5 min with 
10 µM MnCl2 and 4 mM Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated by addition 
of 0.1 to 15 mM BSH or 1 to 100 mM L-cysteine and the mixture allowed to react at room 
temperature.  After 15 and 30 seconds, a 20 µL aliquot of the reaction mixture was quenched by 
addition of 40 µL of 5% (w/v) trichloroacetic acid followed by vortexing.  Addition of 15 µL of 
0.8 M NaOH returned the pH to 7.0.  An internal standard (20 µL of 0.4 mM serine) was added 
and the mixture was diluted to 100 µL with 20 mM HEPES, pH 7.0.  A 20 µL aliquot of the quench 
was added to 55 µL of borate buffer and mixed with 25 µL of the AQC reagent (Waters, Milford, 
MA) solubilized according to the manufacturer’s directions.  Derivatization reaction mixtures were 
incubated at 55 °C for 10 minutes followed by dilution with 400 µL of Mobile Phase A (70 mM 
NaOAc, pH 5.0; 7 mM trimethylamine). 
Derivatized samples were analyzed on an Agilent 1260 Infinity HPLC System using 
fluorescence detection with excitation at 250 nm and emission at 395 nm.  Samples were injected 
onto a 250 mm x 4.6 mm Kinetex C-18 column with a particle size of 5 µm and a pore size of 100 
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Å (Phenomenex, Torrance, CA) and equilibrated with 90% Mobile Phase A and 10% Mobile Phase 
B (80% (v/v) acetonitrile).  Samples were eluted using a flow rate of 1 mL/min and the following 
gradient of Mobile Phase B:  10% from 0 to 6 minutes, 15 to 40% from 15 to 19 minutes, and 40 
to 100% from 19 to 22 minutes.  BS-Fos, L-cys-Fos, and serine had retention times of 4.0, 4.7, and 
7.5 minutes, respectively.  The amount of product formed was quantified as previously described.  
Initial rate measurements for the production of BS-Fos or L-cys-Fos were calculated using the 
slope of amount of product formed vs. time.  All measurements were made in triplicate and 
averaged.  The data were fit to the Michaelis Menten equation (Equation 1) where X is the substrate 
concentration and Y is the enzyme velocity.  Values of Vmax and KM were determined using 
Equation 1 and GraphPad Prism software (La Jolla, CA).  The kcat value was determined using 
Equation 2. 
 
Equation 1: 𝑌 =
𝑉𝑚𝑎𝑥∙𝑋
𝐾𝑀+𝑋
   Equation 2: 𝑉𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡[𝐸] 
 
Expression of FosBBc for Crystallography 
 A pET-20b expression plasmid containing the gene encoding non-tagged WT FosBBc was 
transformed into E. coli BL21 (DE3) cells.  The plasmid was prepared as previously described.  
The cells were plated on LB agar containing 100 µg/mL of ampicillin and incubated with 37 °C 
for approximately 16 h.  Single colonies were isolated from the LB-agar plates and used to 
inoculate 2 mL of LB (Gibco) starter cultures (3 cultures for a total of 6 mL) containing 80 µg/mL 
of ampicillin.  After approximately 8 hours of incubation at 37 °C with shaking, 1 mL of starter 
growth was used to inoculate 1 L of Terrific Broth containing 80 µg/mL of ampicillin (6 L total).  
The 1 L cultures were grown at 37 °C with shaking for approximately 12 hours (or until the OD600 
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reached ~1) and then induced with 0.5 mM IPTG.  Upon induction with IPTG, the temperature 
was reduced to 25 °C, and the cells were allowed to grow for an additional 4 to 5 hours.  The cells 
were harvested via centrifugation at 5000g for 15 minutes. 
 The E. coli cell pellet was resuspended in 2 mL of lysis buffer (20 mM Tris HCL, pH 7.5) 
per gram of cell pellet.  Lysozyme was added to the slurry at 1 mg/mL and the mixture was stirred 
at 4 °C for 1 hour.  After 1 hour of stirring, 5 mg of DNase and RNase were added and the slurry 
was stirred at 4 °C for another hour.  The slurry was sonicated to ensure complete lysing of cells 
and the lysate was cleared via centrifugation at 35000g for 30 min. 
 An ammonium sulfate precipitation was performed on the cleared lysate solution prior to 
any column purification.  Fractions were precipitated at 5, 20, 40, 60, 80, and 95% ammonium 
sulfate.  The fractions were analyzed by SDS-PAGE, and fractions containing the highest ratio of 
FosB to other proteins were combined for further purification.  The protein was dialyzed overnight 
in 20 mM HEPES, pH 7.0 to remove any residual lysis buffer or salt that could interfere with ion-
exchange chromatography. 
 The collected fractions were pooled, concentrated, and loaded onto a GE Healthcare 
HiPrep DEAE FF 16/10 column, equilibrated with 20 mM HEPES, pH 7.0 using an Amersham 
Pharmacia Biotech  FPLC (equipped with a 50 mL super loop).  With an estimated pI of 5.22, 
FosBBc adheres to the DEAE material, and a purple hue can be seen on the column.  The protein 
was eluted from the column at 2 mL/min using a gradient of 0-30% NaCl in the same buffer.  
Fractions were analyzed for purity by SDS-PAGE.  The most pure fractions were collected, 
combined, and dialyzed overnight into 10 mM sodium phosphate, pH 7.0. 
 The protein, in 10 mM sodium phosphate, pH 7.0, was subsequently loaded onto a 2.5 X 
15 cm hydroxyapatite column (BioRad, Hercules, CA).  FosBBc adheres to the hydroxyapatite 
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material.  The protein was eluted from the column with an increasing concentration of phosphate.  
The protein eluted between 100 and 400 mM phosphate according to fraction analyzed by SDS-
PAGE. 
 Finally, the protein was dialyzed into 50 mM sodium phosphate, pH 7.5; 150 mM NaCl, 5 
mM DTT.  The protein was concentrated to approximately 1 mL with an Amicon 10K molecular 
weight cutoff membrane and loaded onto a GE Healthcare 26/60 Sephacryl column at 1 mL/min 
using an Amersham Pharmacia Biotech FPLC.  Fractions were collected from the column at 0.5 
mL each and analyzed for purity by SDS-PAGE. 
 The purified FosBBc protein was prepared with Mn2+, Ni2+, and Co2+ by dialyzing into 
50 mM Bis-Tris, pH 6.0; 5 mM EDTA; 2 mM 1,10-phenanthroline; 3 g Chelex resin.  This ensured 
the removal of all metals.  The protein was divided into fractions and dialyzed into 20 mM HEPES, 
pH 7.5 containing 200 µM of the respective divalent metal. 
 
FosBBc Crystallization 
 Initial crystals of FosBBc were grown using the hanging-drop vapor-diffusion method at 
298 K by mixing 3 µL of protein solution (13 mg/mL in 20 mM HEPES, pH 7.5) and 3 µL of 
reservoir solution (Hampton Research Index 92, 0.1 M magnesium formate and 15% polyethylene 
glycol (PEG) 3350 (w/v)) in a Hampton Research VDX plate.  Crystallization hits were obtained 
in several different conditions, but those grown in HR Index 92 yielded the best diffraction.  The 
final optimized conditions for each crystal are as follows.  For FosBBc with Zn2+ and sulfate and 
FosBBc with Zn2+ and Fos, crystals used for SAD phasing were obtained after mixing equal 
volumes of (3 µL) of the protein solution (13 mg/mL in 20 mM HEPES, pH 7.5) and reservoir 
solution (0.1 M magnesium formate and 12% (w/v) PEG 3350).  The FosBBc with Zn2+ and sulfate 
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crystal used for molecular replacement was obtained after mixing equal volumes (3 µL) of the 
protein solution (13 mg/mL in 20 mM HEPES, pH 7.5; 3 mM BSH; 5 mM DTT) and reservoir 
solution (0.1 M magnesium formate and 9% (w/v) PEG 3350).  For FosBBc with Ni2+, Co2+, or 
Mn2+ and Fos, crystals were obtained after mixing equal volumes (3 µL) of the protein solution 
(13 mg/mL in 20 mM HEPES, pH 7.5; 5 mM Fos; 200 µM M2+) and reservoir solution (0.1 M 
magnesium formate and 12% (w/v) PEG 3350, 10% (w/v) PEG 3350, or 12% (w/v) PEG 3350 for 
Ni2+, Co2+, or Mn2+, respectively).  For FosBBc with Mn2+ and L-cys-Fos, crystals were obtained 
after mixing equal volumes (3 µL) of the protein solution (13 mg/mL in 20 mM HEPES, pH 7.5; 
5 mM Fos; 5 mM L-cysteine; 5 mM DTT; incubated for ~1 hour on ice) and reservoir solution 
(0.1M magnesium formate and 14% (w/v) PEG 3350).  For FosBBc with Zn2+, L-cysteine, and Fos, 
crystals were obtained after mixing equal volumes (3 µL) of the protein solution (13 mg/mL in 20 
mM HEPES, pH7.5; 5 mM Fos; 5 mM L-cysteine; and 5 mM DTT; incubated for ~1 hour on ice) 
and reservoir solution (0.1 M magnesium formate and 8% (w/v) PEG 3350).  For FosBBc with 
Mn2+ and BS-Fos, crystals were obtained after mixing equal volumes (3 µL) of the protein solution 
(13 mg/mL in 20 mM HEPES, pH 7.5; 8 mM Fos; 8 mM BSH; 5 mM DTT; incubated for ~1 hour 
on ice) and reservoir solution (0.1 M magnesium formate and 14% (w/v) PEG 3350).  All crystals 
were cryo-protected in the mother solution and 15% glycerol prior to freezing in liquid nitrogen 
and data collection. 
 
FosBBc Crystal Data Collection and Refinement 
 Screening for the diffraction of crystals was performed at the Biomolecular 
Crystallography Facility in the Vanderbilt University Center for Structural Biology using a Bruker-
Nonius Microstar rotating anode X-ray generator equipped with a Proteum PT 135 CCD area 
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detector mounted on an X8 kappa goniometer with Montel confocal multilayer optics.  Crystals 
were maintained at 100 K using a Bruker KryoFlex cryostat. 
 Diffraction data for all crystals were collected at 100 K on the LS-CAT 21-ID beamline at 
the APS synchrotron facility.  The collected diffraction data sets were processed with HKL2000.36  
Phasing of diffraction data was done either by molecular replacement using PHASER or by SAD 
phasing using SHELXD/E.37  For SAD phasing, the presence of the anomalous scatterer was 
confirmed and the peak wavelength determined by X-ray fluorescence.  Two anomalous scatterers 
were located in the asymmetric unit corresponding to two active sites in the enzyme.  In the case 
of SAD phasing, initial models were constructed using ARPwARP.38  For molecular replacement, 
the first model output and refined from ARPwRP was used as the initial search model.  All crystals 
belong to the P212121 space group and contain 276 amino acids in the asymmetric unit, which 
represents the complete FosBBc enzyme.  Manual model building for each structure was performed 
using Coot model building software.39  Water molecules were placed with the Coot routine, Find 
Waters.  The final models were obtained by iterative cycles of model building in Coot and structure 
refinement using Refmac5 in the CCP4 suite of programs (Collaborative Computational Project, 
1994).40  All protein figures were prepared with Chimera.41  Data collection and refinement 
statistics are given in Table A1 in the Appendix. 
 
 
FosBBc X-ray Fluorescence Spectroscopy 
 All X-ray fluorescence spectra of the crystals were collected at 100 K on the LS-CAT21-
ID beamline at the APS synchrotron facility and used without further processing. 
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Table 3. Data collection and refinement statistics for FosBBc. 
 
Table 1. Data Collection and Refinement Statistics.
FosB/Zn/Sulf SAD FosB/Zn/Sulf MR FosB/Zn/Fos SAD FosB/Ni/Fos SAD FosB/Co/Fos SAD FosB/Mn/Fos MR FosB/Mn/Cys-Fos MR FosB/Zn/Cys-Fos MR FosBMn/BSH-Fos MR
PDB code 4JH1 4JH2 4JH3 4JH4 4JH5 4JH6 4JH7 4JH8 4JH9
Space group P 212121 P 212121 P 212121 P 212121 P 212121 P 212121 P 212121 P 212121 P 212121
Unit-cell prameters
     a  (Å) 64.45 64.34 64.34 64.41 64.33 64.49 64.29 64.31 56.48
     b  (Å) 68.20 68.09 68.27 68.54 68.23 68.69 68.31 68.54 64.48
     c  (Å) 69.60 69.77 69.90 70.44 69.88 70.09 70.18 69.85 83.91
Data collection
Temperature (K) 100 100 100 100 100 100 100 100 100
Wavelength (Å) 1.2823 1.0781 1.2823 1.4847 1.6046 1.1272 1.0781 1.0781 1.1272
Resolution (Å)
a
48.71-1.55 48.73-1.27 48.84-1.50 49.12-1.89 48.82-1.77 49.06-1.32 48.95-1.55 48.92-1.41 51.13-1.77
(1.61-1.55) (1.29-1.27) (1.55-1.50) (1.93-1.89) (1.80-1.77) (1.34-1.32) (1.58-1.55) (1.43-1.41) (1.83-1.77)
Unique reflections 44556 81296 49820 25035 30425 72030 44593 59747 30311
Completeness (%)
a
98.3 (85.2) 99.8 (99.2) 98.8 (94.2) 98.4 (97.0) 98.8 (95.6) 97.8 (99.9) 97.9 (95.6) 99.1 (97.6) 99.2 (92.7)
Rmerge (%)
b
9.3 (52.9) 7.6 (36.1) 9.5 (60.3) 12.6 (79.2) 9.5 (39.8) 5.1 (54.8) 6.6 (45.3) 4.8 (56.2) 8.4 (60.1)
I/σ 27.5 (2.8) 46.0 (5.8) 23 (3.3) 36.6 (5.4) 64.2 (9.0) 32.19 (2.0) 30.1 (3.6) 43.5 (3.0) 12.0 (2.1)
Redundancy 8.5 (4.7) 7.1 (7.0) 9.3 (7.1) 14.2 (14.1) 13.3 (13.0) 4.0 (3.7) 7.4 (7.3) 7.3 (7.1) 4.7 (4.4)
Refinement
Rwork/ Rfree (%)
c
13.33/18.78 12.41/15.16 12.36/16.83 17.22/21.62 16.94/20.93 13.79/17.05 13.33/18.64 13.72/17.41 18.30/23.55
Average B factor (Å
2
)
  All atoms 18.17 14.80 17.67 19.28 17.33 20.38 15.67 19.74 26.37
  Protein 17.01 13.34 16.25 19.03 16.90 19.62 14.55 18.66 26.15
  Water 28.59 24.20 28.25 23.53 22.77 26.82 23.11 26.83 28.67
No. of atoms
  Protein 2640 2938 2707 2484 2546 2702 2682 2751 2524
  Water 258 379 315 142 185 250 259 253 135
Rmsd from ideal
  Bond length (Å) 0.021 0.023 0.021 0.020 0.023 0.023 0.021 0.023 0.019
  Bond angle (deg) 1.96 2.28 1.95 2.02 2.20 2.20 2.07 2.30 1.97
Ramachandran plot (%)
d
  Most favored 234 234 234 235 234 234 232 232 230
  Allowed 16 16 16 15 16 16 18 18 20
  Disallowed 2 2 2 2 2 2 2 2 2
a
Values in parentheses are for the highest resolution shell.  
bRmerge = ∑(│I-Ī│)/∑I x 100.  cRwork = ∑|Fo – Fc|/∑Fo x 100, where Fo is the observed structure factor amplitude and Fc is the calculated structure factor amplitude.  
d
Values are given as number of residues.
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Expression of N-Terminal Hexa-His-Tagged FosBSa for Crystallography 
 The hexa-His-tagged FosBSa gene was amplified from the FosBSa-pET28 plasmid 
previously prepared for kinetic assays using primers containing restriction sites for Nde I and EcoR 
I.  To prepare the N-terminal hexa-His-tagged FosBSa construct, the forward primer was 5’-GC 
GGG GCC GGG GGT ATA CAT ATG CAT CAT CAT CAT CAT CAC TTA AAA TCT ATT 
AAT C-3’ and the reverse primer was 5’- GCC GGC GCC CGG AAT TCG CTT ATT TGT AAA 
ATG-3’.  The underlined parts of primer sequences are complementary to the nucleotide sequences 
of the FosBSa pET28 gene, whereas the 5’ overhanging ends of primers contain recognition sites 
for restriction endonucleases (bold) and are designed to facilitate cloning. 
 The PCR solution consisted of 200 ng of pET28(FosBSa), each primer at 10 µM, and 45 
µL of Platinum PCR SuperMix.  For PCR, 35 cycles were performed with a temperature profile 
of 30 seconds at 95 °C, 30 seconds at 55 °C, and 1 minute at 72 °C in an Applied Biosystems 
(Foster City, CA) 2720 thermal cycler.  The amplification products were analyzed by 
electrophoresis on a 0.8% agarose gel stained with ethidium bromide. 
 The amplification products (1 µg) and pET20b vector (1µg) were digested with Nde I and 
EcoR I.  The digested DNA was analyzed by electrophoresis as previously described; the 
corresponding bands on the gel were excised and the DNA was extracted with a QIAquick Gel 
Extraction Kit (Qiagen).  Purified hexa-His-tagged FosBSa and non-tagged FosBSa were each 
ligated into pET20b Nde I-EcoR I sites.  E. coli XL1-blue supercompetent cells were transformed 
with the ligation mixture and four colonies were assayed for the presence of the FosBSa gene 
fragment by plasmid extraction and plasmid DNA sequencing. 
 The new pET-20b expression plasmid containing the gene encoding hexa-His-tagged 
FosBSa was transformed into E. coli BL21 (DE3) cells.  The cells were plated on LB-agar 
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containing 100 µg/mL ampicillin and incubated at 37 °C for approximately 16 hours.  Single 
colonies were isolated from the LB-agar plates and used to inoculate 2 mL LB (Gibco) starter 
cultures (3 cultures for a total of 6 mL) containing 80 µg/mL of ampicillin.  After approximately 
8 hours of incubation at 37 °C with shaking, 1 mL of starter growth was used to inoculate 1 L of 
Terrific Broth containing 80 µg/mL of ampicillin (6 L total).  The 1 L cultures were grown at 37 
°C with shaking for approximately 12 hours (or until the OD600 reached ~1) and then induced with 
0.5 mM IPTG.  Upon induction with IPTG, the temperature was reduced to 25 °C, and the cells 
were allowed to grow for an additional 4 to 5 hours.  The cells were harvested via centrifugation 
at 5000g for 15 minutes. 
 The E. coli cell pellet was resuspended in 2 mL of His tag lysis buffer (50 mM sodium 
phosphate, pH 8.0; 300 mM sodium chloride; 10 mM imidazole) per gram of cell pellet.  Lysozyme 
was added to the slurry at 1 mg/mL and the mixture was stirred at 4 °C for 1 hour.  After 1 hour 
of stirring, 5 mg of DNase and RNase were added and the slurry was stirred at 4 °C for another 
hour.  The slurry was sonicated to ensure complete lysing of cells and the lysate was cleared via 
centrifugation at 35000g for 30 min. 
 The cleared lysate containing the hexa-His-tagged FosBSa was added to a nickel-NTA 
purification column.  The column was washed with 50 mM sodium phosphate, pH 8.0; 300 mM 
sodium chloride; 20 mM imidazole to remove any protein impurities.  Finally, the hexa-His-tagged 
FosBSa protein was eluted from the nickel-NTA column with 50 mM sodium phosphate, pH 8.0; 
300 mM sodium chloride; 250 mM imidazole.  Following elution from the column, the FosBSa 
protein was dialyzed against 20 mM HEPES, pH 7.5 for crystallization trials. 
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N-Terminal Intein-Tagged FosBSa Crystallization 
 FosBSa purified for kinetic analyses was dialyzed against 25 mM HEPES, pH 7.5; 50 mM 
NaCl for crystallization trials.  Crystals of intein-tagged FosBSa with the exogenous L-Cys-Cys9 
disulfide bond were grown using the hanging drop vapor diffusion method at 303 K by mixing 3 
µL of protein solution (20 mg/mL in 25 mM HEPES, pH 7.5; 50 mM NaCl; 10 mM MgCl2; 10 
mM L-cysteine; and 10 mM Fos) and 3 µL of reservoir solution (Hampton Research Index 68, 0.1 
M HEPES, pH 7.5; 200 mM ammonium sulfate; 25% (w/V) PEG 3350) in a Hampton Research 
VDX plate.  Apo crystals of intein-tagged FosBSa were grown via the same approach with the 
addition of 10 mM tris(2-carboxyethyl)phosphine (TCEP) to the initial protein solution.  These 
crystals were cryo-protected with 25% ethylene glycol in 75% mother liquor. 
 
N-Terminal Hexa-His-Tagged FosBSa Crystallization 
 Initial crystals of hexa-His-tagged FosBSa were grown using the hanging drop vapor 
diffusion method at 303 K by mixing 3 µL of protein solution (8 mg/mL in 20 mM HEPES, pH 
7.5) and 3 µL of reservoir solution (Hampton Research Index 67, 0.1 M Bis-Tris, pH 6.5; 200 mM 
ammonium sulfate; 25% (w/v) PEG 3350) in a Hampton Research VDX plate.  The final optimized 
conditions for each crystal are as follows.  The FosBSa crystals with Zn2+ and sulfate used for SAD 
phasing and molecular replacement were obtained after mixing equal volumes (3 µL) of protein 
solution (7.5 mg/mL in 20 mM HEPES, pH7.5; 5 mM Fos) and reservoir solution (0.1 M Bis-Tris, 
pH 6.5; 200 mM ammonium sulfate, and 16% (w/v) PEG 3350).  The FosBSa crystals with BSH 
were obtained after mixing equal volumes (3 µL) of protein solution (7.5 mg/mL in 20 mM 
HEPES, pH 7.5; 5 mM Fos; 5 mM BSH) and reservoir solution (0.1 M Bis-Tris, pH 6.5; 200 mM 
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ammonium sulfate; 16% (w/v) PEG 3350).  All crystals were cryo-protected in 30% glycerol and 
70% mother liquor and frozen in liquid nitrogen prior to collection of the diffraction data. 
 
FosBSa Crystal Data Collection and Refinement 
 Diffraction data for all crystals were collected at 100 K on either the LS-CAT 21-ID 
beamline at the APS synchrotron facility or the Bruker-Nonius Microstar rotating anode X-ray 
generator at Vanderbilt University.  The collected diffraction data sets from LS-CAT 21-ID were 
processed with HKL2000, whereas those collected on the Bruker instrument were processed with 
Bruker-AXS (2010) PROTEUM2 version 2010.11 (Bruker-AXS, Madison, WI).36  Phasing the 
diffraction data was done either by SAD phasing using SHELXD/E or by molecular replacement 
using PHASER37  For SAD phasing, the presence of anomalous scatterers were confirmed and the 
peak wavelength was determined by X-ray fluorescence.  In the case of SAD phasing, the initial 
model was constructed using ARPwARP.38  For molecular replacement, the first model output and 
refined from ARPwARP was used as the initial search model.  Manual model building for each 
structure was performed using Coot model building software.39  Waters were placed with the Coot 
routine, Find Waters.  The final models were obtained by iterative cycles of model building in 
Coot and structure refinement using Refmac5 in the CCP4 suite of programs.40  All protein figures 
were prepared with Chimera.41  Data collection and refinement statistics are listed in Table A2 in 
the Appendix. 
 
Continuous 31P-NMR Activity Assays of FosBSa with Zn2+.  
Intein-tagged FosBSa (0.5 µM) was equilibrated for 5 min with 100 µM ZnCl2 and 8 mM 
Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated by addition of 1.8 mM BSH or L-
cysteine, transferred to an NMR tube, and allowed to react at 298 K.  At various time points, a 31P 
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with 1H decoupling NMR spectrum was collected using Bruker AV-400 MHz NMR.  Analysis of 
the data was completed according to the method previously described for activity assays with Mg2+ 
or Ni2+. 
  
Table 4. Data collection and refinement statistics for FosBSa. 
 
aValues in parentheses are for the highest-resolution shell.  bRmerge = ∑(|I – I̅|)/∑I × 100.  cRwork = 
∑|Fo – Fc|/∑Fo × 100, where Fo is the observed structure factor amplitude and Fc is the calculated 
structure factor amplitude.  dValues are numbers of residues. 
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Time Point High Performance Liquid Chromatography (HPLC) Activity Assays of FosBSa with 
Mn2+ and Mn2+ with Zn2+.  
Intein-tagged FosBSa (0.5 µM) was equilibrated for 5 min with either 10 µM MnCl2 or 10 
µM MnCl2 and 100 µM ZnCl2 and 4 mM Fos in 20 mM HEPES, pH 7.0.  The reaction was initiated 
by addition of 1.5 mM BSH or 1.8 mM L-cysteine and the mixture allowed to react at room 
temperature.  At various time points, a 20 µL aliquot of the reaction mixture was quenched by 
addition of 40 µL of 5% (w/v) trichloroacetic acid followed by vortexing.  Addition of 15 µL of 
0.8 M NaOH returned the pH to 7.0.  An internal standard (20 µL of 0.4 mM serine) was added 
and the mixture was diluted to 100 µL with 20 mM HEPES, pH 7.0.  A 20 µL aliquot of the quench 
was added to 55 µL of borate buffer and mixed with 25 µL of the AQC reagent (Waters, Milford, 
MA) solubilized according to the manufacturer’s directions.  Derivatization reaction mixtures were 
incubated at 55 °C for 10 minutes followed by dilution with 400 µL of Mobile Phase A (70 mM 
NaOAc, pH 5.0; 7 mM trimethylamine). 
Derivatized samples were analyzed on an Agilent 1260 Infinity HPLC System using 
fluorescence detection with excitation at 250 nm and emission at 395 nm.  Samples were injected 
onto a 250 mm x 4.6 mm Kinetex C-18 column with a particle size of 5 µm and a pore size of 100 
Å (Phenomenex, Torrance, CA) and equilibrated with 90% Mobile Phase A and 10% Mobile Phase 
B (80% (v/v) acetonitrile).  Samples were eluted using a flow rate of 1 mL/min and the following 
gradient of Mobile Phase B:  10% from 0 to 6 minutes, 15 to 40% from 15 to 19 minutes, and 40 
to 100% from 19 to 22 minutes.  BS-Fos, L-cys-Fos, and serine had retention times of 4.0, 4.7, and 
7.5 minutes, respectively.  The amount of product formed was quantified as previously described.16 
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Disk Diffusion Assay 
[The work described in this section was performed by Dr. Neal Hammer from Dr. Eric Skaar’s 
lab.] 
 Soft agar was inoculated with an overnight culture of Newman or USA300 JE2 methicillin-
resistant S. aureus isolate and poured over a tryptic soy agar plate.  Four sterile Whatman paper 
discs were placed on top of the cooled soft agar.  The indicated amounts of Fos were added to each 
disk from a 50 mg/mL stock.  The plates were incubated overnight at 37 °C. 
 
Expression of Native FosBSa for HDX-MS Analyses 
The new pET-20b expression plasmid containing the gene encoding non-tagged FosBSa 
was transformed into E. coli BL21 (DE3) cells.  The cells were plated on LB-agar containing 100 
µg/mL ampicillin and incubated at 37 °C for approximately 16 hours.  Single colonies were 
isolated from the LB-agar plates and used to inoculate 6 mL LB (Gibco) starter cultures (6 cultures 
for a total of 36 mL) containing 100 µg/mL of ampicillin.  After approximately 16 hours of 
incubation at 37 °C with shaking, one starter culture was used to inoculate 1 L of Terrific Broth 
containing 100 µg/mL of ampicillin (for a total of 6 L of large cultures).  The 1 L cultures were 
grown at 37 °C with shaking for approximately 3 hours (or until the OD600 reached 0.5-0.8) and 
then induced with 0.1 mM IPTG.  Upon induction with IPTG, the temperature was reduced to 18 
°C, and the cells were allowed to grow for an additional 16 to 20 hours.  The cells were harvested 
via centrifugation at 6500 X g and 4 °C for 10 min. 
Cell pellets were resuspended in lysis buffer (20 mM Tris HCL, pH 8.5) and 2 Complete 
Mini Protease Cocktail Inhibitor tablets (Roche Diagnostics) were added.  Lysozyme (0.5 mg/mL) 
was added and the mixture was stirred at 4 °C for 20 min.  After 20 minutes, 5 mg of DNase and 
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RNase were added and the slurry was stirred at 4 °C for 2 hours.  Cells were further lysed by 
sonication (50% power, 60% duty cycle, and 2 min on, 3 min off) on ice, until they were no longer 
viscous.  Cellular debris was cleared by centrifugation at 30000 x g and 4 °C for 30 min. 
An ammonium sulfate precipitation was performed on the cleared lysate solution prior to 
any column purification.  Fractions were precipitated at 30, 70, and 90% ammonium sulfate.  The 
fractions were analyzed by SDS-PAGE, and fractions containing the highest ratio of FosB to other 
proteins were combined for further purification.  The collected fractions were pooled, 
concentrated, and dialyzed overnight in DEAE Buffer A (20 mM Tris HCL, pH 8.5; 5% glycerol) 
to remove any residual lysis buffer or salt that could interfere with ion-exchange chromatography. 
 The dialysis was loaded onto a GE Healthcare HiPrep DEAE FF 16/10 column, 
equilibrated with DEAE Buffer A using an Amersham Pharmacia Biotech FPLC (equipped with a 
50 mL super loop).  With an estimated pI of 7.9, FosBSa does not adhere to the DEAE material at 
this pH.  The protein was eluted from the column at 2 mL/min at 100% DEAE Buffer A before 
increasing to 50% of DEAE Buffer B (20 mM Tris HCL, pH 8.5; 1 M NaCl; 5% glycerol).  
Fractions were analyzed for purity by SDS-PAGE.  The most pure fractions were collected, 
combined, and dialyzed overnight against DEAE Buffer C (20 mM Tris HCL, pH 9.0; 5% 
glycerol). 
 The dialysis was loaded onto a GE Healthcare HiPrep DEAE FF 16/10 column, 
equilibrated with DEAE Buffer C using an Amersham Pharmacia Biotech FPLC (equipped with a 
50 mL super loop).  The protein was eluted from the column at 2 mL/min at 100% DEAE Buffer 
C before increasing to 50% of DEAE Buffer D (20 mM Tris HCL, pH 9.0; 1 M NaCl; 5% glycerol).  
Fractions were analyzed for purity by SDS-PAGE.  The most pure fractions were collected, 
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combined, and dialyzed overnight against SP Buffer (20 mM Tris HCL, pH 8.5; 150 mM NaCl; 
5% glycerol). 
 The protein was concentrated to approximately 1 mL with an Amicon 10K molecular 
weight cutoff membrane and loaded onto a GE Healthcare 26/60 Sephacryl S-100 HR column at 
1 mL/min using an Amersham Pharmacia Biotech FPLC.  Protein was eluted from the column 
with SP Buffer.   Fractions were collected from the column at 0.5 mL each and analyzed for purity 
by SDS-PAGE.  The purified FosBSa protein was collected, combined and concentrated with an 
Amicon 10K molecular weight cutoff membrane.  The final sample was dialyzed against 4 liters 
of 20 mM Tris HCL, 8.5; 1 mM EDTA; 6 g Chelex resin.  This ensured the removal of all metals 
before storing 1.7 mM FosBSa at -80 °C. 
 
FosBSa Peptide Sequencing by Tandem Mass Spectrometry 
 Prior to HDX-MS analyses, non-tagged FosBSa was sequenced by LC-MS/MS.  The 
protein was brought to a final concentration of 40 µM in H2O at a volume of 50 µL.  Digestion 
was performed on ice for five minutes by the addition of 2 µL of 200 mg/mL Protease XVIII in 
H2O.  The resulting peptides were separated by reversed-phase HPLC on an ice-cold Phenomenex 
Aeris Peptide 3.6 µ XB-C18 50 X 21 mm column and eluted at a flow rate of 0.1 mL/min with a 
thirty minute gradient of 5-95% acetonitrile and 0.4% formic acid.  Scans of m/z 300 to 2000 were 
utilized for peptide detection using positive electrospray ionization on a ThermoFinnigan LTQ 
linear ion trap mass spectrometer at the Mass Spectrometry Core Lab at Vanderbilt University.  
Peptides were sequenced by data-dependent MS/MS by CID.   
The putative identity of each peptide was determined using the computational program 
PEAKS Client 6 (Bioinformatics Solutions Inc.), which determines the identity of peptide 
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fragments from raw data.42  PEAKS predicts peptide fragmentation based on the type of protease 
used, the FASTA sequence for the protein, MS instrument used, and the parameters used for MS.  
Experimental fragmentation patterns are matched with predicted peptide fragmentation.  The false 
discovery rate (FDR) is calculated for the match using decoy sequences and is reported as a -
10log(p) value, where p is the probability that a false identification of the current search has the 
same or better significance.   
All peptides with a -10log (p) value greater than 20 (equal to a p value of 0.01) were 
selected and verified using MassXpert MS analysis software.43  This presents all possible peptides 
within the protein with the same parent mass as experimental data.  Then the experimental 
fragmentation spectra will be compared to theoretical fragmentation patterns of the possible 
peptides generated by ProteinProspector program MS-Product.44 Verified peptides were combined 
to create a peptide coverage map. 
 
Amide HDX-MS 
 Analyses of backbone amide H/D exchange were performed on FosBSa in the presence of 
Mn2+, Mn2+ and Fos, or Mn2+, Fos, and BSH.  HDX-MS analyses were completed using the 
continuous labeling method.  Prior to deuterium incorporation, 200 µM FosBSa samples were 
combined with 200 µM MnCl2, or 200 µM MnCl2 and 20 mM Fos and incubated for 5 minutes at 
room temperature.  If required, 20 mM BSH was added to the sample immediately prior to 
deuterium incorporation.  Deuterium incorporation was initiated by a five-fold dilution of 10 µL 
of the pre-incubated protein solution in 99.9% atm D2O at room temperature (final concentrations 
were 40 µM FosBSa, 40 µM MnCl2, 4 mM Fos, or 4 mM BSH).  The incorporation was quenched 
at various time points between 15 seconds to 8 hours by a two-fold dilution in ice-cold 100 mM 
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KH2PO4, pH 2.3.  The protein was digested on ice for five minutes by addition of 2 µL of 200 
mg/mL protease XVIII in H2O.  The resulting peptides were separated by reversed-phase HPLC 
on an ice-cold Phenomenex Aeris Peptide 3.6 µ XB-C18 50 X 21 mm column and eluted at a flow 
rate of 0.1 mL/min with a fifteen minute gradient of 5-95% acetonitrile and 0.4% formic acid.  All 
samples were prepared individually and run on the same day.  Scans of m/z 300 to 2000 were 
utilized for peptide detection using positive electrospray ionization on a ThermoFinnigan LTQ 
linear ion trap mass spectrometer at the Mass Spectrometry Core Lab at Vanderbilt University. 
 Deuterium incorporation was observed as a shift in the centroid ion envelope for each 
peptide.  In order to correct for deuterium incorporation that occurs after the quenching step, a 
control for time point zero (m0%) was performed, in which 10 µL of the pre-incubated protein was 
solution was added to 40 µL of H2O at room temperature followed by quenching and digestion 
with protease XVIII as described above.   
 The spectra from each HDX-MS sample were analyzed using the program HDExaminer 
(Sierra Analytics).42  The program determines the centroids of the isotope envelope for each 
peptide at each HDX time point using a program-specific algorithm and a list of known peptide 
fragments with their respective retention times.  After analysis, each peptide centroid was manually 
optimized for the best fit of the known peptide.  HDExaminer determines the number of deuterons 
incorporated onto each peptide using Equation 3, correcting for the loss and gain of deuterium 
during the analysis, where D is the number of deuterons incorporated, N is the total number of 
exchangeable backbone amides, mt is the average mass of the partially deuterated peptide sample 
at time t, and m0% and m100% are the average masses of the non-deuterated and fully deuterated 
peptide control samples, respectively.  For this analysis, the theoretical m100% determined by the 
HDExaminer program was used. 
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Equation 3: 𝐷 = 𝑁(
𝑚𝑡−𝑚0%
𝑚100%−𝑚0%
) 
 
Each experiment was repeated in duplicate and averaged.  The percentage of deuterium 
incorporation for each peptide was plotted as a function of log time using Kaleida-Graph (Synergy 
Software).  The resulting plot was fit to the sum of first-order rate expressions using Equation 4, 
where N is the total number of exchangeable hydrogens and Ai is the number of amide protons 
that exchange at the rate ki for the exchange time t. 
 
Equation 4: 𝐷 = 𝑁 − ∑ 𝐴𝑖 × 𝑒
−𝑘𝑖𝑡𝑛
𝑖−1  
 
Mass spectrometric analysis of purified BshC.  
The native BshC enzyme was analyzed for the presence of tightly-bound ligands utilizing 
liquid chromatography-mass spectrometry prior to cleavage with rTEV protease. The BshC 
preparation (approximately 1 nmol of protein in 50 mM ammonium bicarbonate, pH 7.5) was 
separated by HPLC on a 50 mm x 2.1 mm Phenomenex Aeris Peptide C18 column with 3.6 µm 
particle size. Protein with bound substrate was eluted with a 10 minute gradient from 5-95% 
acetonitrile with 0.4% formic acid. The spectra were obtained in negative mode at various voltages 
(5-15 V) utilizing a ThermoFinnigan LTQ linear ion trap mass spectrometer at the Mass 
Spectrometry Core Lab at Vanderbilt University. Peaks of 112.7 m/z, 158.7 m/z, 262.7 m/z, and 
425.7 m/z were observed, and a peak search was conducted at MassBank.45 The 112.7 m/z, 158.7 
m/z, and 425.7 m/z peaks are suggestive of adenosine nucleosides, whereas the 262.7 m/z has no 
match in the database. These data suggest that adenosine nucleosides are present in the sample, 
but their exact identity cannot be confirmed.  
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CHAPTER III 
 
DETERMINATION OF THE CATALYTIC SELECTIVITY OF THE FOSFOMYCIN 
RESISTANCE ENZYME, FosB1 
 
Results 
 The discovery of the new LMW thiol in Gram-positive bacteria, BSH, in 2009 implicated 
that BSH could be the primary substrate for FosB activity instead of the previously reported L-
cysteine.19  However, BSH was not commercially available and the biosynthetic pathway was not 
fully elucidated and confirmed in vitro.  Therefore, to begin investigating the possibility that FosB 
is a BSH-transferase, we needed to obtain stable BSH that could be utilized to initiate both kinetic 
and structural studies.  
The Vanderbilt Institute of Chemical Biology (VICB) Chemical Synthesis Core developed 
a novel 11 step synthesis of bacillithiol disulfide (BSSB) utilizing D-glucosamine as a starting 
point with an overall 8-9% yield.46  While these synthetic studies were underway, Hamilton and 
coworkers reported the chemical synthesis of BSH starting with D-glucal.  Shortly thereafter, BSH 
became commercially available at a cost of $225/mg.  The synthesis developed by the VICB 
Chemical Synthesis Core provided our lab with over one gram of BSSB at a cost of approximately 
$15/mg, which is 15 fold cheaper than the commercially available BSH.  Additionally, BSSB is 
                                                        
1 Reprinted with permission from Lamers, A. P., Keithly, M. E., Kim, K., Cook, P. D., Stec, D. F., 
Hines, K. M., Sulikowski, G. A., and Armstrong, R. N. (2012) Synthesis of Bacillithiol and the 
Catalytic Selectivity of FosB-Type Fosfomycin Resistance Proteins, Org Lett 14, 5207-5209. 
Copyright 2012 American Chemical Society. 
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more stable than BSH for storage and use.  It can also readily be reduced to BSH for use in kinetic 
assays and structural studies.   
 
A New Continuous 31P NMR Method  
 Upon receipt of BSSB, I used a commercially available thiol reduction column to develop 
a reduction method of BSSB to afford BSH in 45% yield.  I then developed a new continuous 31P 
NMR activity assay for FosB enzymes, which was used to begin investigating substrate and metal 
ion selectivity using time course kinetic analyses of FosB from four Gram-positive organism: 
Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, and Bacillus anthracis (FosBSa, FosBBs, 
FosBBc, and FosBBa respectively).  While this NMR assay is quick and convenient, it cannot be 
utilized with paramagnetic metals or for performing detailed steady-state kinetic analyses.   
 The enzymatic inactivation of Fos by FosB was initiated in a 3 mM NMR tube and 
continuously monitored at various time points by 31P with 1H decoupling NMR spectroscopy.  
Figure 13 shows representative NMR spectra with Cys-Fos, Bs-Fos, and Fos peaks, which have 
the unique chemical shifts of 18.9, 18.6, and 12.1 ppm respectively.  The exact chemical shifts are 
pH dependent, but are always distinct for the substrates and products.  The NMR assays contained 
an excess of Fos in order to allow the use of the law of conservation of mass to calculate the amount 
of product formed.  The spectra collected for each time point were used to calculate the peak height 
of Fos substrate and the BS-Fos or Cys-Fos product.  The amount of product formed was calculated 
from the ratio between the peak heights of substrate and product and the total concentration of Fos 
used in the reaction. 
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Figure 13. Representative spectra of the new continuous 31P NMR assay.  This is a spectra of a mixed 
enzymatic assay, which shows unique chemical shifts for Cys-Fos, BS-Fos, and Fos peaks of 18.9, 18.6, 
and 12.1 ppm respectively. 
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Time Course Kinetic Analyses of FosB Inactivation of Fosfomycin 
Access to BSH allowed for screening of FosB enzymes from several different bacterial 
species.  Each enzyme was analyzed using time course kinetics with the continuous 31P NMR 
analysis previously described. The assays were completed with L-cysteine, and BSH as possible 
thiol substrates.  Metal dependent activation of these enzymes was analyzed using the diamagnetic 
metals Ni2+ and Mg2+.   
Figure 14 shows results for FosBSa, FosBBs, FosBBc, and FosBBa.   The results indicate a 
very clear preference of the FosBSa enzyme for BSH and Ni2+, but no activity with L-cysteine in 
the presence of Mg2+.  The FosBBs, FosBBc, and FosBBa enzymes also show an increase in activity 
with BSH compared to L-cysteine, but it is a moderate increase in FosBBc and FosBBa.  These data 
also show that the unlike FosBSa, activation of FosB from the bacilli species with Ni2+ and Mg2+ 
is similar. 
While the NMR assay is not suitable for analyzing detailed steady-state kinetics, the results 
can be used to estimate the approximate minimum turnover numbers (kcat) from the initial rates of 
the reactions (Table 3).    The apparent kcat for FosB
Sa with BSH and Ni2+ is ~30 s-1, but with Mg2+ 
drops to ~1 s-1.  FosBSa activity with L-cysteine and Ni2+ also drops to ~0.9s-1.  The apparent kcat 
for FosBBs with BSH and Ni2+ or Mg2+ are ~6 s-1 and ~3 s-1, respectively.  With L-cysteine the kcat 
values are much lower, on the order of 0.05 to 0.2 s-1. 
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Table 5. Apparent kcat values determined from FosB time course activity assays. 
Strain Metal Thiol Apparent kcat (s-1) 
FosBSa Ni2+ BSH 30 
FosBSa Mg2+ BSH 1 
FosBSa Ni2+ L-cysteine 0.9 
FosBSa Mg2+ L-cysteine unable to determine 
FosBBs Ni2+ BSH 6 
FosBBs Mg2+ BSH 3 
FosBBs Ni2+ L-cysteine 0.2 
FosBBs Mg2+ L-cysteine 0.05 
FosBBc Ni2+ BSH 1.7 
FosBBc Mg2+ BSH 1.7 
FosBBc Ni2+ L-cysteine 0.6 
FosBBc Mg2+ L-cysteine 0.2 
FosBBa Ni2+ BSH 1.7 
FosBBa Mg2+ BSH 2.1 
FosBBa Ni2+ L-cysteine 0.4 
FosBBa Mg2+ L-cysteine 0.3 
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Figure 14. Time course kinetic analyses of FosB inactivation of Fos.  Time course of the FosBSa , FosBBs , FosBBc and FosBBa 
catalyzed-addition of BSH or L-cysteine to fosfomycin in the presence of Mg2+ or Ni2+ shown in panels A, B, C, and D, 
respectively. Reactions were carried out at 25˚ C in 20 mM HEPES, pH 7.0 with 4 mM fosfomycin and 0.5 µM enzyme in the 
presence of () 2 mM BSH and 10 µM Ni2+, () 2 mM BSH and 1 mM Mg2+, () 2 mM L-cysteine and 10 µM Ni2+ or () 2 
mM L-cysteine and 1 mM Mg2+. 
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Discussion 
 The new chemical synthesis of BSSB developed by the VICB chemical synthesis core 
provided our lab with stable BSH at an affordable cost.  This allowed us to begin preliminary 
analysis of the substrate selectivity for the FosB enzymes from multiple bacterial species.  Upon 
receipt of the BSSB, a commercially available reduction column was used to obtain BSH at a 45% 
yield.  A new continuous 31P NMR assay was developed to use for analysis of time course enzyme 
assays.  This assay is quick and easy to use for time course kinetic assays.  However, it is unsuitable 
for use with paramagnetic metals or for detailed steady state kinetics. 
The NMR assay was used to complete the initial analysis of FosB enzymatic activity with 
L-cysteine compared to BSH.  Additionally, we probed the metal dependent activation of FosB by 
both Ni2+ and Mg2+.  The results of the time course kinetic analyses show a clear preference for 
BSH over L-cysteine as the in vitro thiol substrate for FosB enzymes from several Gram-positive 
organisms.  However, between the two diamagnetic metals tested, there preference for FosB 
activation was not as clear.  While FosBSa showed a significant increase in activity when Ni2+ was 
present, the FosB enzymes from bacilli species had no preference between Ni2+ and Mg2+. 
In conclusion, the newly described synthesis of BSSB opens the door for more detailed 
kinetic and metal-ion preference studies of the FosB enzymes as well as structural investigation of 
the FosB enzyme in complex with BSH and products.  FosB was originally described as an Mg2+-
dependent L-cysteine-transferase, but the results of these initial time-course kinetic analyses 
indicate the FosB is actually a BSH-transferase.  While we know the enzyme is dependent on a 
divalent metal, further investigation of multiple divalent metals was required to determine the best 
activating metal-ion cofactor. 
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CHAPTER IV 
 
ANALYSIS OF THE STRUCTURE AND FUNCTION OF FosB FROM Bacillus cereus 
REVEALS FosB IS A MANGANESE-DEPENDENT BACILITHIOL-TRANSFERASE2 
 
Results 
Time Course Kinetic Analyses of FosBBc Inactivation of Fosfomycin 
 The metal activation of FosBBc by Mg2+ and Ni2+ were previously investigated, but the 
divalent activation of the FosB enzymes remained unclear.46  It is possible that metal activation 
may be dependent upon the organism containing the FosB enzyme.  To further probe the 
appropriate divalent metal activation of FosBBc, kinetic analyses for the inactivation of Fos by the 
nucleophilic addition of L-cysteine or BSH in the presence of Mg2+, Ni2+, and Zn2+ were conducted 
utilizing the continuous 31P NMR method previously described in Chapter II of this work.   
Additionally, kinetic analysis of FosB activation by Mn2+ was completed using a modified 
version of the continuous 31P NMR assay.  Since Mn2+ is a paramagnetic metal and will interfere 
with the NMR assay, the reaction was quenched and metal was removed for ten different time 
points ranging from 30 sec to 60 min.  Each time point was analyzed by 31P NMR and the spectra 
were processed in the same manner as those run using the continuous assay.   
Initial reactions were conducted at 298 K in 20 mM HEPES, pH 7.0 with 8 mM Fos and 
0.5 µM FosBBc in the presence of 4 mM BSH or L-cysteine and 10 mM Mg2+ or 100 µM Zn2+ 
                                                        
2 Reprinted with permission from Thompson, M. K., Mary. E.; Harp, Joel; Cook, Paul D.; 
Jagessar, Kevin L.; Sulikowski, Gary A.; Armstrong, Richard N. (2013) Structural and 
Chemical Aspects of Resistance to the Antibiotic Fosfomycin Conferred by FosB from Bacillus 
cereus, Biochemistry 52, 7350-7362.  Copyright 2012 American Chemical Society. 
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(Figure 15).  The concentration of Mg2+ was selected to be significantly greater than Kact (~200 
µM) reported for the homologous FosBBs enzymatic activity with L-cysteine as the thiol 
substrate.17  The results revealed that Zn2+ is a potent inhibitor of FosBBc activity with both L-
cysteine and BSH. 
 
 
Additional reactions to test metal activation by Mn2+, Ni2+, or Mg2+ were conducted with 
half the enzyme and co-substrate concentrations (Figure 16).  This change was necessary because 
the inactivation of Fos by addition of BSH in the presence of Mn2+ is so efficient that the initial 
observable time point via the NMR method using the higher concentrations was beyond 
completion.  The concentration of Mg2+ was also reduced to 1 mM to more accurately reflect the 
 
Figure 15. Time course kinetic analysis of FosBBc catalyzed addition of BSH or L-cysteine to 
Fos in the presence of Mg2+ and Zn2+.  Reactions were carried out at 25˚ C in 20 mM HEPES, 
pH 7.0 with 8 mM fosfomycin and 0.5 µM enzyme in the presence of () 4 mM BSH and 10 
mM Mg2+, () 4 mM L-Cys and 10 mM Mg2+, () 4 mM BSH and 100 µM Zn2+,  or () 4 
mM L-Cys and 100 µM Zn2+. 
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prevailing intracellular concentrations of the metal.  Reduction of the Mg2+ concentration had no 
effect on the results. 
The apparent kcat values for FosB
Bc with each metal and thiol substrate were approximated 
from the data.  The apparent kcat for FosB
Bc with BSH and Mn2+, Ni2+, or Mg2+ are 26.7 s-1, 1.3 s-
1, and 1.0 s-1 respectively.  The apparent kcat for FosB
Bc with L-cysteine and Mn2+, Ni2+, or Mg2+ 
are 2 s-1, 0.6 s-1, and unable to be determined respectively.  The results demonstrate that FosBBc 
has a distinct preference for BSH over L-cysteine with metal activation in vitro as follows:  
Mn2+>Ni2+>Mg2+.  Therefore, FosBBc is a Mn2+-dependent BSH-transferase.   
 
  
 
Figure 16. Time course kinetic analysis of FosBBc catalyzed addition of BSH or L-cysteine to 
Fos in the presence of Mg2+, Ni2+, or Mn2+.  Reactions were carried out at 25˚ C in 20 mM 
HEPES, pH 7.0 with 4 mM fosfomycin and 0.25 µM enzyme in the presence of ( ) 2 mM 
BSH and 10 µM Mn2+, () 2 mM BSH and 10 µM Ni2+, () 2 mM BSH and 1 mM Mg2+, () 
2 mM L-cysteine and 10 µM Mn2+ () 2 mM L-cysteine and 10 µM Ni2+,  or () 2 mM L-
cysteine and 1 mM Mg2+. 
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Steady State Kinetic Analyses of FosB Inactivation of Fosfomycin 
 In order to compare the catalytic efficiency of FosBBc inactivation of Fos by nucleophilic 
addition of BSH in the presence of Mn2+, steady state kinetic analyses were completed.  An 
endpoint high performance liquid chromatography (HPLC) assay with fluorescence detection of 
ACCQ-Fluor derivatized samples was used to complete the analysis using both L-cysteine and 
BSH as substrates and Mn2+ for metal activation.  Figure 17 shows the Michaelis Menten plots of 
this analysis and the calculated steady state kinetic constants can be found in Table 4.  
 
 
The increase in activity with BSH compared to L-cysteine correlates with the similar 
increase in activity seen during the time course analyses previously described.  There is also a 10-
fold increase in activity with L-cysteine with Mn2+ compared to published data for FosBBs activity 
with L-cysteine and Mg2+ (kcat/Km
thiol is 180 M-1s-1).17  The results for FosBBc show that the catalytic 
efficiency of FosB activity with BSH and Mn2+ is an order of magnitude lower than would be 
expected to account for in vivo activity.  While this work was in progress, Roberts et al. published 
mechanistic studies of FosBSa.  Our results correlate with the data published for FosBSa (kcat/Km
thiol 
is 4 X 103 M-1s-1).47 
 
Table 6. Steady state kinetic constants for the FosBBc catalyzed addition of BSH or L-
cysteine to Fos in the presence of Mn2+.  
Thiol Vmax (M/s) kcat (s-1) kcat/KMthiol (M-1s-1) KMthiol (mM) 
L-cysteine 3.39 X 10-5 135.6 1.3 X 103 104 
BSH 2.12 X 10-5 84.8 1.0 X 104 8.4 
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Figure 17. Steady state kinetic analysis of FosBBc catalyzed addition of BSH or L-cysteine to Fos 
in the presence of Mn2+.  Reactions were carried out at 25˚ C in 20 mM HEPES, pH 7.0 with 4 
mM Fos and 0.25 µM enzyme in the presence of 10 µM Mn2+ and (A) 1-100 mM L-cysteine or 
(B) 0.1-15 mM BSH.  The green line represents Vmax for each analysis.   
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Crystal Structure Determination of FosBBc 
 Nine high resolution crystal structures of FosBBc in complex with various combinations of 
divalent metals, substrates, or products were determined.  The crystal structure of FosBBc•Zn2+ 
(PDB 4JH1) was refined to 1.55 Å resolutions.  An X-ray fluorescence scan of the crystal prior to 
diffraction data collection confirmed the presence of a high concentration of Zn2+ (Figure 18).  
Diffraction data was then collected at the Kα absorption edge of Zn
2+, which is a wavelength of 
1.28 Å.  Phases were determined by single wavelength anomalous diffraction (SAD) from the Zn2+ 
kα edge and Zn
2+ was used to model the observed density.   
Using a similar method of data collection, structures of FosBBc•Zn2+•Fos (PDB 4JH3), 
FosBBc•Ni2+•Fos (PDB 4JH4), and FosBBc•Co2+•Fos (PDB 4JH5) were determined to 1.49 Å, 1.89 
Å, and 1.77 Å resolutions respectively.  Each diffraction data set was collected at the Kα absorption 
edge of Zn2+, Ni2+, or Co2+ (1.28 Å, 1.48 Å, or 1.61 Å respectively) and initial phases were 
determined by SAD phasing of the corresponding divalent metal for each structure (Figures 19-
21) .  X-ray fluorescence scans of each crystal prior to diffraction data collection was used to 
confirm the presence of each metal (Figures 18, 22-23). 
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Figure 19.  Overall X-ray crystal structure of FosBBc•Zn2+•Fos at 1.50 Å resolution (PDB 
4JH3).   The anomalous density map from the SAD experiment shown around the Zn2+ metal 
ions is contoured at 5 σ.  Rwork = 12.36% and Rfree = 16.83%. 
 
Figure 18. X-ray fluorescence scans of the FosBBc•Zn2+ crystals.    
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Figure 20.  Overall X-ray crystal structure of FosBBc•Ni2+•Fos at 1.89 Å resolution (PDB 
4JH4).   The anomalous density map from the SAD experiment shown around the Ni2+ metal 
ions is contoured at 5 σ.  Rwork = 17.22% and Rfree = 21.22%. 
 
Figure 21.  Overall X-ray crystal structure of FosBBc•Co2+•Fos at 1.77 Å resolution (PDB 
4JHH).   The anomalous density map from the SAD experiment shown around the Co2+ metal 
ions is contoured at 5 σ.  Rwork = 16.94% and Rfree = 20.93%. 
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Figure 22. X-ray fluorescence scans of the FosBBc•Ni2+•Fos crystal.    
 
Figure 23. X-ray fluorescence scans of the FosBBc•Co2+•Fos crystal.    
 62 
Co-crystallization of FosBBc in the presence of BSH resulted in higher quality crystals, but 
the BSH molecule was never observed in the structure.  This resulted in a 1.27 Å structure of 
FosBBc•Zn2+•SO42- (PDB 4JH2) determined by molecular replacement.  Crystals of FosBBc grown 
in the presence of Zn2+, Fos, and L-cysteine produced electron density that is not clearly the product 
or the Fos and L-cysteine cosubstrates.  The structure of FosBBc•Zn2+•Fos•L-cysteine (PDB 4JH8) 
was determined to 1.41 Å resolution and solved by molecular replacement.  The electron density 
of carbon-1 of Fos appears more substrate-like in character and the strong electron density above 
carbon-1 is most certainly that of sulfur.  The ambiguity of the remaining electron density for L-
cysteine is likely caused by a combination of occupancy and multiple conformations in the solvent 
channel. 
Structures of FosBBc•Mn2+•Fos (PDB 4JH6), FosBBc•Mn2+•L-cysteine-Fos (PDB 4JH7), 
and FosBBc•Mn2+•Bs-Fos (PDB 4JH9) were determined to 1.32 Å, 1.55 Å, and 1.55 Å resolutions 
respectively using molecular replacement.  Crystals were analyzed by X-ray fluorescence prior to 
diffraction data collection to confirm the presence of Mn2+ (Figure 24).  However, due to the longer 
wavelength of the Kα absorption edge of Mn
2+ (1.89 Å), which can damage protein crystals during 
data collection, these structures were solved by molecular replacement instead of SAD phasing.  
The B factors for each of the metal sites in the crystal indicate Mn2+ ions are a good fit for the 
observed electron density.  A library file in CIF format for (1R,2S)-1-(S-L-cysteinyl)-2-
hydroxypropylphosphonate product was created using the online PRODRG Server and inserted 
into the model for FosBBc•Mn2+•L-cysteine-Fos.48  The same product was used to model the 
observed density in the active site of FosBBc•Mn2+•Bs-Fos because the glucosamine-malate 
domain of BSH was not observed (Figure 25).  It is likely that this is not observed because the 
glucosamine-malate moiety is simply not homogenous in the crystal.  Protein flexibility is critical 
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for proper enzyme function and the rigidity of the crystal may prevent proper seating of the BSH 
molecule in the enzyme. 
 
  
 
Figure 24. X-ray fluorescence scans of the FosBBc•Mn2+•Fos crystal.    
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Structural Characterization of FosBBc 
As anticipated, the overall structure reveals that FosB is a homodimer belonging to the 
VOC superfamily of metalloenzymes similar to the other Fos resistance enzymes, FosA and FosX 
(Figure 26).18  The structures contain a 3D domain-swapped arrangement of tandem βαβββ motifs 
in which both subunits of the homodimer participate in formation of the active site, which is a 
characteristic feature of the VOC superfamily.3  Like the FosA and FosX enzymes, FosB also 
 
Figure 25. The active site of FosBBc in complex with Mn2+ in the presence of BS-Fos at 1.77 
Å resolution (PDB 4JH9).  The model was refined with L-cys-Fos since the complete density 
for BS-Fos is missing.  Final refinement had a Rwork = 18.30% and Rfree = 23.55%.  The 
difference electron density shown for product is contoured 3σ.  The unit cell dimensions for 
this crystal are different than the others reported (Table 1) indicating a significant difference 
in crystal packing.  That product has been formed is evidenced by opening of the epoxide ring 
of the antibiotic and a C1-S bond length of 1.85 Å.  Unlike what is observed in the 
FosBBc•Mn2+•L-cys-Fos structure, the electron density in this structure weakens near the Cα 
end of the L-cysteinyl domain.  Thus, what is observed in this structure is the phosphonate end 
of Bs-Fos tethered to the Mn2+ metal within the enzyme while the glucosamine-malate moiety 
of BS-Fos solvent exposed and disordered on the surface of the enzyme within the crystal. 
E115
H66
H7
C9
Y39
Y105
R94
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utilizes two histidines and a glutamic acid to coordinate the metal ion.  Additionally, the structure 
in complex with Fos and various divalent metals establishes the presence of Fos coordinated to 
Zn2+, Ni2+, Co2+, or Mn2+ (PDBs 4JH1, 4JH4, 4JH5, and 4JH6; Figure 27A).  Similar to the FosA 
structure in complex with Fos, the geometry of metal coordination for FosBBc with bound Fos is a 
highly distorted, five-coordinate trigonal bipyramidal configuration with His7, His66, and the 
phosphonate oxygen of Fos in the equatorial sites and Glu115 and the oxirane oxygen of Fos in 
the axial sites. 
 
 
 FosBBc in complex with Mn2+ and the L-cysteine-Fos product was determined at 1.55 Å.  
In this structure, the epoxide ring of Fos is opened via nucleophilic addition of L-cysteine to 
 
Figure 26. Overall X-ray crystal structure of FosBBc in complex with Mn2+ and Fos at 1.32 Å 
resolution (PDB 4JH6).  Rwork = 13.79% and Rfree = 17.05% 
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carbon-1 of Fos. Carbon-1 is sp3 hybridized and strong electron density is observed for the sulfur. 
The L-cysteine-Fos product (constructed in PRODRG according to the stereochemistry reported 
by Bernat et al.) is identified as (1R,2S)-1-(S-L-cysteinyl)-2-hyrdoxypropylphosphonate, the same 
product as that reported for FosA (Figure 27B).15a, 48  Inversion of the configuration at carbon-1 
indicates that the reaction proceeds via direct SN2 addition of the thiol to the oxirane carbon. 
 The crystals of FosBBc grown in the presence of Zn2+, Fos, and L-cysteine produced 
electron density that most closely resembles the Fos and L-cysteine cosubstrates (Figure 27C).  
The density of the Fos carbon-1 is more substrate-like in geometry than that of the product complex 
seen in Figure 27B.  Additionally, the electron density above carbon-1 of Fos has a peak of 17.30σ, 
which is too intense for even the most well-ordered water molecules.  When refined with L-
cysteine, the sulfur atom has a B factor of 27.1 Å2 averaged over the two sites, which compares 
quite well with the overall B factor for the structure of 19.7 Å2.  Furthermore, the oxygen of Tyr39 
is 3.25 Å from the sulfur and the location of the sulfur superimposes that of the thioether of L-
cysteine-Fos in the FosBBc•Zn2+•Fos•L-cysteine structure.  Finally, the distance between carbon-1 
of Fos and the sulfur is 2.79 Å, which is significantly shorter than the theoretical van der Waals 
interaction of 3.50 Å and much longer than a typical carbon-sulfur single bond (1.83 Å).  This 
likely represents the location of the sulfur when it is poised for nucleophilic attack of Fos.  This 
structure represents a ternary structure with both substrates in the active site, which is an 
anticipated result because Zn2+ is a potent inhibitor of FosBBc activity. 
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 Superposition of the FosBBc•Zn2+•Fos•L-cysteine ternary structure and the FosBBc•Mn2+• 
L-cysteine-Fos product structure shows that Asn50 is the only residue that changes position in the 
active site.  In the ternary structure, Asn50 is oriented approximately 90° relative to the product 
structure.  This positions the Oδ of Asn50 4.13 Å from the Fos carbon-1 and Nδ of Asn50 4.20 Å 
from the sulfur of L-cysteine. 
 
Figure 27. Stereo views of (A) FosBBc•Mn2+•Fos (PDB 4JH6), (B) FosBBc•Mn2+•L-cysteine-Fos 
(PDB 4JH7), and (C) FosBBc•Zn2+•Fos•L-cysteine (PDB 4JH8). Difference densities are the 
2Fo–Fc maps calculated before addition of the ligands to the coordinate files and are contoured 
at 3σ. The electron density in (A) shows the position of Fos coordinated to Mn2+. The electron 
density in (B) shows L-cysteine-Fos coordinated to Mn2+. The carbon-1 density of L-cysteine-Fos 
is sp3 hybridized following nucleophilic attack by the thiol. The electron density in (C) shows 
Fos coordinated to Zn2+ and the density for carbon-1 of Fos is more substrate-like in geometry 
than that of (B), indicating no product formation. The strong electron density above carbon-1 
likely belongs to sulfur. The ambiguity in the rest of the density for the L-cysteine is probably 
due to a combination of occupancy and multiple conformations in the crystal. 
 
 68 
 Surface analysis of the FosBBc structures revealed a well-defined pocket and access channel 
to carbon-1 of Fos (Figure 28).  The pocket and access channel are appropriate in size and shape 
to accommodate L-cysteine or BSH.  The positioning of Fos in the active site is oriented to place 
the backside of carbon-1 directly in the center at the end of the solvent access channel.  This is 
necessary for nucleophilic addition of the thiol to Fos.   
 
Discussion 
 Initial crystallization of FosBBc contained Zn2+ in the active site (PDBs 4JH1 4JH2, and 
4JH3), which is similar to a structure deposited in the PDB for FosBBa (PDB 4IR0).  The presence 
of the metal was confirmed using X-ray fluorescence and SAD phasing from the Kα edge of Zn
2+.  
These crystals were grown from purified FosBBc grown in terrific broth media without further 
 
Figure 28. Surface analysis of FosBBc in complex with Fos (PDB 4JH3).  (left) Top-view of the 
channel from the surface of the protein into the active site. The green line contours a depression in 
the surface of the protein large enough to accommodate BSH. (right) Narrowing of the channel 
near Fos (shown in stick representation). The narrow section (outlined in red) is large enough to 
accommodate either L-cysteine or the cysteinyl moiety of BSH.  
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manipulation to add or remove specific metals.  Therefore, Zn2+ was the divalent metal “selected” 
by the enzyme during growth.  Given that the Zn2+ was the “selected” metal, we tested the Zn2+ 
activation of FosBBc for both L-cysteine and BSH transferase activity.  The results indicate that 
Zn2+ inhibits activity of FosBBc (Figure 15), which prompted additional kinetic analyses of the 
FosBBc enzyme. 
 Initial analysis of divalent metal activation of FosBBs nucleophilic addition of L-cysteine 
to Fos established the activation order as Ni2+ ~ Mg2+ > Mn2+ > Fe2+ > Cu2+ > Ca2+ ~ Co2+ > Zn2+.17  
However, our access to BSH allowed us to screen several FosB enzymes for BSH transferase 
activity.  The results demonstrate that the four enzymes tested (FosBSa, FosBBs, FosBBa, and 
FosBBc) have a preference for BSH over L-cysteine as the thiol substrate in vitro.46  The more 
extensive kinetic analyses of FosBBc presented in this chapter demonstrates a preference for BSH 
over L-cysteine and establishes the metal activation of FosBBc in vitro to be Mn2+ > Ni2+ > Mg2+ > 
Zn2+ (Figures 15 and 16).  This order is in agreement with the homologous classes of Fos resistance 
enzymes, FosA and FosX, where both are activated by Mn2+ and show only minimal activity with 
Zn2+ in the presence of their respective nucleophiles.12, 49 
 Steady state kinetic analysis of Mn2+-dependent FosBBc inactivation of Fos by nucleophilic 
addition of L-cysteine or BSH was completed.  This analysis revealed a moderate increase in 
FosBBc BSH transferase activity compared to FosBBc L-cysteine transferase activity (Table 4).  
There was also a 10-fold increase in FosBBc L-cysteine transferase activity compared to published 
data for Mg2+-dependent FosBBs L-cysteine transferase activity.  The catalytic efficiency of Mn2+-
dependent FosBBc BSH transferase activity (kcat/Km
thiol is 1.0 X 104 M-1s-1) is an order of magnitude 
lower than the reported Mn2+-dependent FosA GSH transferase activity (kcat/Km
thiol is 1.7 X 105 M-
1s-1).12  The FosBBc activity is lower than would be expected to account for the robust in vivo 
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activity of FosB.  However, a steady state kinetic analysis of FosBSa was reported by Roberts et 
al. in 2013 and our results correlate with their published results.47 
 The preference of FosBBc for BSH over L-cysteine suggests that the glucosamine-malate 
domain of the BSH molecule is important for substrate recognition.  In the 2013 study completed 
by Roberts et al., substitution of the malate motif in BSH with either an O-methyl or O-benzyl 
aglycone group results in a 10- and 18-fold increase for the KM
thiol, respectively, in FosBSa.47  This 
indicates that the thermodynamic driving force of the nucleophilic inactivation of Fos is likely the 
interaction of the glucosamine-malate domain with the surface of the enzyme. 
 The surface analysis of FosBBc (Figure 28) revealed a well-defined pocket and access 
channel that is the correct size and shape to accommodate L-cysteine or BSH.  The role of this 
proposed binding pocket and access channel can be elucidated by either FosBBc•Mn2+•L-cysteine-
Fos (PDB 4JH7) or FosBBc•Mn2+•Bs-Fos (PDB 4JH9).  In both structures, the nucleophilic 
addition of the thiolate to carbon-1 of Fos occurs at the end of the channel (Figure 29).  The opening 
of the binding pocket from the access channel begins at the Cα end of the cysteinyl moiety, where 
the remainder of the BSH domain would be connected through the secondary amine of the Bs-Fos 
product.  Unfortunately, in PDB 4JH9, the complete molecule of Bs-Fos was not observed seated 
in the binding pocket of the crystal for reasons previously described. 
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Analysis of Fos coordination to the metal in the active site revealed that the molecule is 
surrounded by a cage of amino acids positioned appropriately to anchor the antibiotic in the 
orientation necessary for nucleophilic attack, placing the backside of carbon-1 in the center of the 
solvent access channel (Figure 30).  This cage has both polar and nonpolar ends to accommodate 
Fos.  The polar phosphonate group of Fos is coordinated to the metal through one of the 
phosphonate oxygens and hydrogen bonded to Arg94, Arg124, Tyr64, and Tyr105 through the 
other two.  The triangular cage structure around the phosphonate is maintained by a salt bridge 
from Arg94 to Asp100 and hydrogen bonds from Arg124 to Tyr39 and Asp100.  The oxirane 
oxygen of Fos is coordinated to the metal such that the methyl group of Fos is held adjacent to 
Trp46 and carbon-2 of Fos is pointed directly at Ala48.  These amino acids that construct the cage 
structure are conserved throughout the FosB enzymes (Figure 31, green). 
 
Figure 29. Active site of FosBBc in complex with Mn2+ and L-cysteine-Fos at 1.55 Å resolution 
(PDB 4JH7).  The difference electron density of L-cysteine-Fos is the 2Fo-2Fc map calculated 
before the addition of the molecule to the coordinate file and is contoured at 3σ.  Rwork = 13.33% 
and Rfree = 18.64%.  
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Figure 30. Fos molecule surrounded by a cage of amino acids.  The cage consists of a polar and nonpolar end to accommodate Fos.  The 
polar phosphonate group of Fos is coordinated to the metal through one of the phosphonate oxygens and hydrogen bonded to Arg94, Arg124, 
Tyr64, and Tyr105 through the other two.  The oxirane oxygen of Fos is coordinated to the metal such that the hydrophobic methyl group 
of Fos is held adjacent to Trp46.  These amino acids that construct the cage structure are conserved throughout the FosB enzymes. 
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Figure 31.  Sequence alignment of current FosB enzymes.  Residues highlighted in blue are the metal coordinating amino acids.  
Residues highlighted in green for the Fos cage.  Residues highlighted in red are involved in activation. 
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The conserved Arg94 and Asp100 residues that form the salt bridge of the loop region in 
FosB that encloses the Fos phosphonate group are not present in FosA.  This region of the FosA 
enzyme is composed of amino acids that form the K+ binding loop.  This explains why K+ is 
required for the optimum activation of FosA, but not for FosB. 
Tyr39 is a conserved residue in both the FosA and FosB enzymes.  Mutation of this residue 
to phenylalanine in FosA resulted in a 13-fold reduction in enzymatic turnover and a 50-fold 
decrease in catalytic efficiency for the thiol substrate (kcat/KM
GSH).50  Tyr39 was reported to be in 
a favorable position to ionize GSH in FosA based upon energy-minimized docking.  In the 
FosBBc•Mn2+•L-cysteine-Fos (PDB 4JH7) and FosBBc•Zn2+•Fos•L-cysteine (PDB 4JH8) 
structures, Tyr39 is approximately 3.31 Å from the L-cysteine sulfur, which is consistent with the 
docking results for GSH to FosA.  Therefore, the function of Tyr39, in FosA or FosB, is likely to 
abstract a proton from and activate the incoming thiol during the reaction.  Hydrogen bonding of 
Tyr39 to Arg124 would stabilize the tyrosinate anion to facilitate this function (Figure 30). 
In summary, the mechanism of FosB catalyzed inactivation of Fos proceeds via direct SN2 
addition of the thiol to the oxirane carbon.  This forms the same (1R,2S)-1-(S-L-cysteinyl)-2-
hydroxypropylphosphonate (or (1R,2S)-1-(S-bacillithiolyl)-2-hydroxypropylphosphonate) 
product as that formed by FosA.15a  Structural analysis also reveals a cage of amino acids that 
holds Fos in the appropriate position at the bottom of a solvent access channel for nucleophilic 
attack by a thiol.  This indicates that FosB must bind Fos and metal prior to attack by the thiol in 
a binary binding mechanism.  Finally, kinetic analyses reveal that FosB is indeed a Mn2+-
dependent BSH transferase. 
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CHAPTER V 
 
INVESTIGATION OF THE STRUCTURE AND FUNCTION OF FosB FROM Staphylococcus 
aureus CONFIRMS FosB IS INHIBITED BY ZINC AT INTRACELLULAR 
CONCENTRATIONS AND SUGGESTS A HIGHLY CONSERVED LOOP REGION MUST 
CHANGE CONFORMATION UPON FOSFOMYCIN BINDING3 
 
Results 
Time Course Kinetic Analyses of FosBBc Inactivation of Fosfomycin 
 Roberts et al. reported a detailed mechanistic investigation of divalent metal activation of 
FosBSa.47  The results indicated that FosBSa is activated by Zn2+ and has the following metal ion 
activation order:  Zn2+ > Ni2+ > Mn2+ > Mg2+ ~ Fe2+ ~ Co2+ ~ Cu2+ ~ Ca2+.  However, these results 
contradict the metal activation of all other Fos resistance enzymes, including FosA, FosX, FosBBc, 
and FosBBs, in which Zn2+ effectively inhibits any transferase activity.12, 15b, 17, 46, 49, 51  Therefore, 
we were compelled to confirm the reported results. 
 Our time course kinetic analyses (Figure 32) indicate that FosBSa is inhibited for L-cysteine 
transferase activity and only marginally active for BSH transferase activity at physiological 
concentration of Zn2+ (~100 µM) with an apparent kcat
thiol of 0.17 s-1.  We also found that 10 µM 
Mn2+ activates FosBSa BSH transferase activity with an apparent kcat
thiol of 5.98 s-1.  FosBSa L-
cysteine transferase activity is activated by 10 µM Mn2+ with an apparent kcat
thiol of 0.05 s-1.  These 
                                                        
3 Reprinted with permission from Thompson, M. K., Mary. E.; Goodman, Michael C.; Hammer, 
Neal D.; Cook, Paul D.; Jagessar, Kevin L.; Harp, Joel; Skaar, Eric P; Armstrong, Richard N. 
(2014) Structure and Function of the Genomically Encoded Fosfomycin Resistance Enzyme, 
FosB, from Staphylococcus aureus, Biochemistry 53, 755-765. Copyright 2014 American 
Chemical Society. 
 76 
results indicate that FosB has a preference for BSH over L-cysteine and are also consistent with 
reports of metal activation for all other Fos resistance enzymes, including FosA, FosX, FosBBc, 
and FosBBs.  Finally, we found that 100 µM Zn2+ inhibits the reaction even when it is supplemented 
with 10 µM Mn2+ for both L-cysteine and BSH transferase activity.  The apparent kcat
thiol for this 
BSH transferase activity is 0.08 s-1, but it could not be determined for L-cysteine transferase 
activity, which is similar to inhibition by Zn2+ alone. 
 
 
  
 
Figure 32. Time course kinetic analysis of FosBSa catalyzed addition of BSH or L-cysteine to 
Fos in the presence of Mn2+ and/or Zn2+.  Reactions were carried out at 25˚ C in 20 mM HEPES, 
pH 7.0 with 4 mM fosfomycin and 0.50 µM enzyme in the presence of () 1.6 mM BSH and 
10 µM Mn2+, ()1.6 mM BSH and 100 µM Zn2+, () 1.6 mM BSH,  10 µM Mn2+, and 100 
µM Zn2+, () 1.8 mM L-cysteine and 10 µM Mn2+ () 1.8 mM L-cysteine and 100 µM Zn2+,  
or () 1.8 mM L-cysteine 10 µM Mn2+, and 100 µM Zn2+. 
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Disk Diffusion Assays 
 Kinetic analyses have demonstrated that FosB enzymes prefer BSH over L-cysteine as the 
thiol substrate for the nucleophilic inactivation of Fos in vitro.  The detoxification pathway for 
detoxification of xenobiotics, such as Fos, involving BSH has previously been characterized for S. 
aureus in vivo.21  BSH null S. aureus exhibits an increase in Fos sensitivity for both the Newman 
and USA300 JE2 strains, but the question of whether FosB null S. aureus exhibits a similar 
increase in sensitivity to Fos remained.20  In collaboration with Dr. Neal Hammer in the Skaar lab 
we made an effort to answer this.  The Skaar lab conducted Kirby-Bauer disk diffusion assays to 
test for Fos sensitivity in BSH null and FosB null strains of both Newman and USA300 JE2 S. 
aureus, which were obtained from the Network on Antimicrobial Resistance in S. aureus.  As 
anticipated, both of the null strains of USA300 JE2 and Newman show a substantial increase in 
their sensitivity to Fos as seen by the increased zone of clearing (Figure 33).  Furthermore, the 
zone of clearing for the BshA null mutant is comparable to that of the FosB null mutant (Table 5).  
This indicates that both BSH and the FosB enzyme are required for optimal survival of S. aureus 
when it is treated with Fos. 
 
 
Figure 33. Fos disk diffusion assays for USA300 JE2 (MRSA).  The amount of Fos on each 
disk is shown in red: (left) wild-type MRSA, (center) BshA knockout MRSA, (right) FosB 
knockout MRSA. 
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Crystal Structure Determination of FosBSa 
 Five high resolution crystal structures of FosBSa in complex with various combinations of 
divalent metals and substrates were determined.  The crystal structure of FosBSa•Zn2+•SO42- (PDB 
4NAY) was refined to 1.42 Å resolutions (Figure 36).  An X-ray fluorescence scan of the crystal 
prior to diffraction data collection confirmed the presence of Zn2+ (Figure 34).  The diffraction 
data were collected at the Kα absorption edge of Zn
2+, which is a wavelength of 1.28 Å.  The initial 
phases were determined using Zn2+ SAD phasing and the final model consists of amino acids 1-
91 and 102-138 with a sulfate ion coordinated to the metal.  A second crystal of FosBSa•Zn2+•SO42- 
was used to collect another data set at a wavelength of 1.078 Å to achieve higher resolution.  The 
second data set, determined by molecular replacement using PDB 4NAY, resulted in a 1.15 Å 
resolution structure of FosBSa with Zn2+ and sulfate in the active site (PDB 4NAZ – Figure 36).  
The final model also consisted of amino acids 1-91 and 102-139 with a sulfate ion coordinated to 
the metal. 
Table 7. Disk diffusion zones of clearing (mm) for MRSA.  
Strain 10 µg 25 µg 50 µg 100 µg 
WT USA300 JE2 17 18 21 24 
BshA KO 34 33 40 40 
FosB KO 35 33 37 40 
WT Newman 22 24 28 30 
BshA KO 35 37 40 40 
FosB KO 34 34 39 37 
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Figure 34. X-ray fluorescence spectrum of the FosBSa•Zn2+•sulfate crystals. 
 
Figure 35.  Overall X-ray crystal structure of FosBSa•Zn2+•sulfate at 1.15 Å resolution (PDB 
4NAZ).   The structure was solved by molecular replacement using PDB 4NAY.  Rwork = 
13.44% and Rfree = 16.22%. 
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 Co-crystallization of FosBSa with either BSH or L-cysteine resulted in two structures with 
a disulfide bond at the Cys9 residue of FosBSa.  These structures were determined by molecular 
replacement using a homodimer model of the enzyme created from PDB 4NAZ.  The structure 
with a BS-Cys9 disulfide bond was refined to a final resolution of 1.62 Å and the final model 
consists of amino acids 1-53, 62-91, 102-128, and 133-138 for subunit A and 1-53, 63-129, and 
135-138 for subunit B.  The structure with an L-cys-Cys9 disulfide bond was refined to a final 
resolution of 1.62 Å and the final model consists of amino acids 1-52, 61-92, 102-127, and 131-
139 for subunit A and 1-53, 64-128, and 134-138 for subunit B. 
  
 
 
Figure 36. Overall crystal structure of FosBSa with Zn2+ and sulfate in the active site at 1.42 
Å.  The red and blue color scheme indicates each subunit of the homodimer of the enzyme.  
The anomalous density map (magenta) around the Zn2+ metal ions (purple) is contoured to 5σ 
and marks the location of the metal within the structure.  Rwork is 12.95% and Rfree is 16.64%. 
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Co-crystallization of FosBSa with L-cysteine and TCEP reduced the exogenous disulfide 
bond and produced an apo structure of the enzyme.  The final structure was determined by 
molecular replacement to a final resolution of 1.62 Å.  The final model consists of amino acids 1-
56, 62-91, 102-126, and 132-138 for subunit A and 1-53, 63-128, and 135-138 for subunit B. 
 
Structural Characterization of FosBSa 
 Similar to the FosBBc and FosBBa enzymes, FosBSa belongs to the VOC superfamily.51  
Although amino acids 92-101 are not observed in PDBs 4NAY or 4NAZ and are observed in only 
one subunit of PDBs 4NB0, 4NB1, and 4 NB2, the 3D domain-swapped arrangement of sequential 
βαβββ motifs that define the VOC superfamily is still evident in the overall structure (Figure 36).3  
His7, His66, and Glu115 constitute the metal binding site in FosBSa, which are the same as those 
in FosBBc.51  In the FosBSa•Zn2+•SO42- structures, the Zn2+ is in a tetrahedral coordination geometry 
with a sulfate oxygen occupying the fourth coordination site of the metal.  However, this sulfate 
molecule is oriented in a position opposite to that observed in FosBBc, with the second sulfate 
 
Figure 37. The sulfate molecule of FosBSa (left) is oriented in a position opposite that observed 
in FosBBc (right).  In FosBSa, the second sulfate oxygen is hydrogen bonded to the non-metal-
coordinated Oε atom of Glu115, but in FosBBc this is bonded to a highly conserved water 
molecule.   
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oxygen hydrogen bonded to the non-metal-coordinated Oε atom of Glu115 (Figure 37 left).
51  In 
FosBBc (PDB 4JH2), the sulfate is oriented in a position that superimposes the phosphonate moiety 
of Fos and the non-metal-coordinated Oε atom of Glu115 is hydrogen bonded to a highly conserved 
water molecule (Figure 37 right).   
  In the structures of FosBSa with BS-Cys9 or L-cys-Cys9 disulfide bonds and the apo 
structure (PDBs 4NB0, 4NB1, and 4NB2 respectively), amino acids ~90-101 are observed in a 
conformation different from that found in either FosBBc or FosBBa (Figure 38 left).  The two 
different conformations are best described as open, for FosBSa, and closed for both FosBBc and 
FosBBa.  The difference between the open and closed conformations is the absence and presence 
of Fos, respectively.  In the FosBSa structure, the open loop region is wrapped around a sulfate 
molecule (Figure 38 left).   
 
 
Figure 38. Superposition of FosBBc (cyan) and FosBSa (red) (left).  In the  FosBBc structure 
(PDB 4JH6), Mn2+ and Fos are bound in the active site and the conserved phosphonate binding 
loop is observed in the closed conformation.  In the FosBSa structure (PDB 4NB2), there is no 
metal or Fos bound in the active site and the phosphonate binding loop is observed in the open 
conformation.  Superposition of FosBBc and FosBSa with the phosphonate binding loop 
morphed into the closed conformation (right).  The conserved Fos cage residues align after the 
FosBSa structure has been morphed into the FosBBc structure.  
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Of the approximately 11 residues that compose the loop region, eight are conserved 
throughout all FosB enzymes (Figure 39).  The three nonconserved residues are solvent-exposed 
in the closed conformation of the loop in FosBBc (PDB 4JH6) and FosBBa (PDB 4IR0).  The 
conserved residues of the loop constitute important structural features of FosB.  In the closed 
conformation, they form one side of the Fos binding cage with several hydrogen bonding 
interactions to the antibiotic.  They also form one side of the BSH binding pocket.  Additionally, 
the open residues of FosBSa can be morphed into the positions of Fos-bound FosBBc to completely 
form the important substrate binding structural features (Figure 38 right). 
 
 
Structural dynamic studies of FosBSa via HDX-MS 
 Based on the structures determined for FosBSa, FosBBc, and FosBBa, the phosphonate 
binding loop region appears to move from an open conformation to a closed conformation upon 
binding Fos.  Additionally, we have been unsuccessful in determining a structure of FosB with the 
entire molecule of BSH present in the active site.  In an effort to confirm the possible dynamic 
 
Figure 39. Sequence alignment of the phosphonate binding loop residues.  Eight of the eleven 
residues are conserved throughout the FosB enzymes and the non-conserved residues are all 
solvent exposed.    
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loop movement and the location of BSH binding, HDX-MS analysis was completed.  HDX-MS 
data was collected for FosBSa in the following states: (1) bound to Mn2+, (2) bound to Mn2+ and 
Fos, and (3) bound to Mn2+, Fos, and BSH. 
 Prior to collecting HDX-MS data, a peptide map of FosBSa digested with the acidic protease 
XVIII was determined using LC-MS/MS analysis.  The peptide mapping method was optimized 
to achieve 97% coverage of the protein (Figure 40) by testing various quench times ranging from 
3 to 7 minutes.  The coverage map also included multiple peptides for most areas of the protein.  
This includes the phosphonate loop region, which is 100% covered by 6 different peptides.  Based 
on this peptide map, HDX-MS data was collected for FosBSa digested by the protease XVIII. 
 The HDX-MS results of FosBSa in complex with Mn2+, Mn2+ and Fos, or Mn2+, Fos, and 
BSH showed overall low deuterium incorporation (Figure 41).  For the majority of the peptides 
analyzed, deuterium incorporation remained below 50%.  There were also no significant changes 
in the rate of incorporation between the three various enzyme complex states tested.  This indicates 
that the overall structure of FosBSa is relatively stable with little overall dynamic movement. 
Surprisingly, the signals for all six peptides covering the phosphonate binding loop region 
were completely lost when collecting HDX-MS data.  The exact cause of this loss of signal is 
unknown.  However, it is possible that the flexible regions of the protein could be more readily 
digested by the protease.  This would lead to lower amounts of these particular peptides for 
analysis.  Due to time constraints of the HDX-MS method, it is standard procedure to shorten the 
gradient used to separate peptides by 50% compared to the gradient utilized for separation during 
peptide mapping.  Taken together, this could explain the loss of signal for the phosphonate binding 
loop region.  
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Figure 40. Peptide map of FosBSa.  Peptide mapping of FosBSa digested with XVIII was optimized to achieve 97% coverage of the 
protein.  The phosphonate binding loop region (boxed in red) was 100% identified by 6 different peptides.  Additionally, amino acid 
residues that help form the BSH binding cavity (shown as green underlined font) are also well covered by multiple peptides. 
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Figure 41. HDX kinetic profiles of representative peptides for the overall structure of FosBSa.  Shown are the average kinetic profiles 
for the deuterium incorporation as a function of time for FosBSa complexed with either () Mn2+, () Mn2+ and Fos, or () Mn2+, Fos, 
and BSH.  The amino acid residues for each peptide is displayed in the upper left corner of each graph and the number of exchangeable 
amide protons for each peptide is displayed as the y-max value for each graph. 
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Discussion 
The crystal structures of FosBSa all contain the 3D domain-swapped arrangement of 
sequential βαβββ motifs that define the VOC superfamily (Figure 36).  Thus, confirming FosBSa 
is a member of the VOC superfamily similar to the previously described Fos resistance enzymes.  
We were also able to crystallize FosBSa with Zn2+ in the active site of the enzyme, similar to our 
structures of FosBBc, which allowed us to use the metal for SAD phasing of the data.51  The 
anomalous scattering density map in Figure 36 establishes the location of the metal within the 
FosBSa active site. 
The kinetic analyses of FosBSa reported by Roberts et al. indicated that the enzyme is 
activated by Zn2+ and has the following divalent metal ion activation order:  Zn2+ > Ni2+ > Mn2+ > 
Mg2+ ~ Fe2+ ~ Co2+ ~ Cu2+ ~ Ca2+.47  However, the other Fos resistance enzymes, such as FosA, 
FosX, FosBBc, and FosBBs, are inhibited by Zn2+.12, 15b, 17, 46, 49, 51  Additionally, several structures 
of FosBSa and FosBBc with Zn2+ in the active site were determined.  Therefore, we completed time 
course kinetic analyses to reassess the divalent metal activation and/or inactivation of FosBSa. 
While we did not complete full kinetic analyses, we found that FosBSa is inhibited by Zn2+, 
which is as we expected given the activation of the other Fos resistance enzymes.  FosBSa is 
completely inhibited by Zn2+ for L-cysteine transferase activity and only marginally active for BSH 
transferase activity at physiological concentrations of Zn2+ (Figure 30).  The apparent kcat
thiol for 
Zn2+-dependent BSH transferase activity is 0.17 s-1.  By comparison the apparent kcat
thiol for Mn2+-
dependent BSH transferase activity is 5.98 s-1, which is a > 35-fold increase (Figure 32). Most 
interestingly, our assays completed at physiological concentrations of both Zn2+ and Mn2+ 
demonstrate that FosBSa is inhibited for either L-cysteine or BSH transferase activity, similar to 
Zn2+ alone. 
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These results contradict the published result for FosBSa, but are consistent with all other 
reports for this class of enzymes.  The study published by Roberts et al. used concentrations of 
Zn2+ as high as 10 mM in their activation studies, which is physiologically irrelevant.47  
Additionally, an explanation for why this class of enzyme is activated by Mn2+ and inhibited by 
Zn2+ has been presented.  Lastly, the active site residues for each class of Fos resistance enzymes 
are conserved.  Therefore, we believe that inhibition of FosBSa by physiological concentrations of 
Zn2+ is correct.   
Roberts et al. demonstrated that increasing concentrations of BSH appeared to inhibit 
activation of FosBSa by Zn2+ until the concentration of Zn2+ had eclipsed that of BSH.47  From their 
results, they determined that FosBSa and BSH were competing for complexation with Zn2+ and that 
BSH is therefore a sufficiently strong Zn2+ chelator to demetalate the enzyme.  While BSH has 
been suggested to be a M2+ chelator based on the nature of its functional substituents, our crystal 
of FosBSa with disulfide bonds in the active site suggest an alternate explanation.19   
The crystallization conditions (100 mM Bis-Tris, pH 6.5; 5 mM Fos; and 5 mM BSH or 
100 mM HEPES, pH 7.5; 10 mM Fos; 10 mM L-cysteine) are similar to the kinetic assay conditions 
used by Roberts et al. (50 mM HEPES, pH 7.0; 25 mM Fos; 0.5-5 mM BSH).  Also, the change in 
the crystallographic space group from C2 to P1 indicates that the disulfide bond formed in solution 
prior to crystal formation.  Therefore, inhibition of FosBSa by millimolar concentrations of 
exogenous thiol may actually be due to the formation of the thiol-Cys9 disulfide bond and steric 
removal of the metal rather than demetalation of the enzyme but the substrate.   
Even if BSH were in a strong complex with Zn2+, the thiol would be one of the coordinating 
ligands, which would mean it would not be able to serve as a nucleophilic substrate for Fos 
inactivation by FosB.  Our kinetic analyses with Zn2+ and Mn2+ were designed so that even if all 
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of the Zn2+ (100 µM) was in complex with BSH, there is still excess free BSH (1.8 mM) in solution 
to serve as the nucleophilic substrate for FosBSa activated by Mn2+ (10 µM).  Since the reaction 
does not proceed, we conclude that (1) either Zn2+ and Mn2+ are in complex with BSH and there 
is no free metal to activate the enzyme or (2) Zn2+ is competing with Mn2+ in the active site of 
FosBSa and inhibiting the enzyme.  Only the second conclusion is plausible because FosBSa is 
highly active in the presence of Mn2+ and BSH only. 
While FosBBc and FosBBa were both crystallized with Fos coordinated to the metal, we 
have been unsuccessful in obtaining a Fos-coordinated structure of FosBSa even though the 
antibiotic was present in the crystallization solution at a concentration of 5 mM.  This is likely due 
to the crystallization conditions requiring high concentrations of ammonium sulfate (200 mM), 
which competes with Fos for binding in the active site of FosBSa.  Sulfate is isoelectronic with the 
phosphonate moiety of Fos and has been observed in the active sites of the classes of Fos resistance 
enzymes.   
A comparison of our apo FosBSa structure with a Fos and metal coordinated structure of 
FosBBc or FosBBa revealed an interesting loop feature of the FosB enzymes that is composed of 
amino acids 90-100.  In the FosBBc or FosBBa structures, the loop is observed in a conformation 
that encloses the phosphonate end of the polar Fos molecule and represents one side of the Fos 
cage structure of the enzyme.51  The cage is composed of residues Tyr39, Trp46, Ala48, Tyr64, 
Arg94, Asp100, Tyr105, and Arg124, which are all conserved (Figure 30) and is the structural 
feature that locks the antibiotic in the active site.  Fos is held in the proper position with the carbon-
1 poised for nucleophilic attack by L-cysteine or BSH.  In FosBSa, there is a lack of complete 
electron density for the region in PDBs 4NAY or 4NAZ, suggesting a high degree of flexibility.   
In addition, the electron density is observed in PDBs 4NB0, 4NB1, and 4NB2, but the loop is in a 
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conformation best described as open relative to the FosBBc or FosBBa structures (Figure 38).  In 
this open structure, the residues of the loop are wrapped around a sulfate molecule forming five 
hydrogen bond interactions and demonstrating the propensity of the loop to coordinate sulfate or 
the possibly the isoelectronic phosphonate end of Fos.   
In both the FosBBc and FosBBa structures, a narrow access channel leading to carbon-1 of 
Fos is observed.  A cross-sectional area analysis of the access channel at its most narrow point in 
FosBBc revealed that it is approximately 15 Å2 (Figure 42).  The cross-sectional area of the 
phosphonate end of Fos is 19 Å2 (Figure 43).  This narrow channel is optimized to accommodate 
the L-cysteinyl domain of BSH and contains several conserved residues involved in the catalytic 
mechanism of the FosB enzymes.  This raises the question of how Fos enters the active site of 
FosB and we think the opening and closing of the loop region is the answer. 
The loop must be open to allow Fos to enter the active site of FosB.  The hydrophobic 
methyl end of Fos would thermodynamically favor the hydrophobic side of the Fos cage in the 
enzyme.  Once bound, the loop would close around the antibiotic holding it in place directly at the 
end of the access channel poised for nucleophilic attack by the thiol.   Loop closure could 
incorporate the unexplained water molecule, and a combination of hydrogen bonds to the water 
and to Fos would hold the loop in the closed position forming the final side of the BSH binding 
pocket (Figure 28 – Chapter IV).  This is consistent with the substrate binding studies of FosB, 
which indicate that Fos must bind first followed by nucleophilic attack of the thiol cosubstrate.47 
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Figure 42.  The cross-sectional area of the access channel in FosBBc at its most narrow point 
is less than 15 Å2.  The cavity where Fos binds was created using the Surfnet feature of 
Chimera after removing Fos from the coordinate file (PDB 4JH7).  (a) The cavity is shown in 
the surface model of FosBBc.  The default cutoff distances of the Surfnet feature have 
connected several nearby cavities and thus resulted in the large cavity structure shown.  Fos 
has been added back to the coordinate file.  (b) The cavity is shown in a ribbon model of 
FosBBc.  (c) The cavity shown alone with Fos. (d) The cavity rotated 90° to the right from c.  
The black line approximates the clipping plane used to create e.  (e) The measured cross-
sectional area of the clipped surface varies depending on the angle of the cavity to the clipping 
plane but is always less than 15 Å2. 
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In order to investigate the dynamic movement of the loop region, HDX-MS analyses of 
FosBSa in complex with Mn2+, Mn2+ and Fos, or Mn2+, Fos, and BSH were completed.  While 
initial peptide mapping achieved 97% coverage of FosBSa with multiple peptides covering the loop 
region, the signals for all of the peptides covering the loop region were lost during HDX-MS 
analyses.  Therefore, we were unable to utilize this method to confirm the dynamic movement of 
the loop region.  However, the results (Figure 41) did indicate that the rest of the structure is 
relatively stable with little dynamic movement, which was expected based on the multiple crystal 
structures we have determined.  Further investigation of the dynamics of the phosphonate binding 
loop region are needed to confirm the movement of the loop from open to closed upon binding 
Fos. 
Finally, we completed in vivo studies of FosBSa, in collaboration with Dr. Eric Skaar’s lab, 
to further understand the requirements of the enzyme for survival of the pathogen in general.  BSH 
null strains of B. subtilis and S. aureus have been previously examined for Fos sensitivity.  The 
results demonstrate that BSH is necessary for detoxification of xenobiotics from Gram-positive 
 
Figure 43.  The cross-sectional area of the phosphonate end of Fos is 19 Å2.  The surface of 
Fos was generated using chimera (Left).  The Fos molecule was oriented (Center) such that a 
clipping plane could be created through the three phosphonate oxygens (Right).  The cross-
sectional area of the clipping plane is 19 Å2. 
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organisms and that BSH is required for resistance of the organisms to Fos.  Our disk diffusion 
assays show that FosB knockout S. aureus USA300 JE2 and Newman strains demonstrate and 
increase in Fos sensitivity similar to that of the BSH null cells.   
In order to allow for direct comparison of the FosB knockout cells to BSH null cells, we 
included BshA knockout strains in our studies.  The zone of clearing for BSH null USA300 JE2 
null cells treated with 100 µg Fos is 40 mm, which is consistent with the published values of 39, 
40, and 39 mm for BshA, BshB, and BshC knockouts, respectively, of USA300 JE2 treated with 
350 µg Fos.  While the published results use an amount of Fos three times greater than ours, we 
achieved a maximal zone of clearing between 25 to 50 µg Fos and the zone of clearing at 50 µg is 
the same as that for 100 and 350 µg.  Therefore, it appears there is a maximal effectiveness of Fos 
reached for disk diffusion assays somewhere between 25 and 50 µg of Fos.   
Since the zone of clearing for FosB null strains are the same as those for BSH null strains, 
we conclude that both BSH and the FosB enzymes are equally important for the resistance of 
MRSA to Fos, which validates FosB as a potential therapeutic drug target.  Additionally, the fact 
that both FosB and BSH null strains of S. aureus Newman and USA300 JE2 have an equally 
increased sensitivity to Fos indicates that the thiol-dependent FosB detoxification pathway for Fos 
is the primary resistance mechanism of the organism to Fos. 
In summary, we have determined the first high resolution crystal structures of FosBSa, 
which is the enzyme responsible for resistance of the pathogen to Fos.  FosBSa catalyzes the Mn2+-
dependent nucleophilic addition of BSH to Fos and represents the sole inactivating pathway of the 
organism from USA300 JE2 or Newman strains.    The new structures revealed a phosphonate 
binding loop on the enzyme.   We believe this loop functions as a door that opens and closes to 
allow the antibiotic to enter the active site of the enzyme.  Once closed, the loop completes 
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important structural features that bind and secure both cosubstrates.  Analysis of FosBSa via HDX-
MS was unsuccessful at probing the dynamics of the loop region, but did reveal that the over 
structure of FosBSa is relatively stable with little dynamic movement.   
Contrary to published results, we demonstrated that FosBSa is inhibited by Zn2+ similar to 
other Fos resistance enzymes.  Our kinetic results clearly indicate that FosBSa is a Mn2+-dependent 
BSH transferase and inhibited by physiologically relevant concentrations of Zn2+.  Given the 
similarity of the susceptibility of the BSH and FosB null strains of MRSA to Fos, we can predict 
the MIC values of FosB null MRSA to be 10-20 µg/mL based on the reported value for BSH null 
strains.  This is below the reported serum concentration of Fos following the standard 3 g dose.  
Therefore, targeting FosBSa therapeutically could serve as a synergistic treatment for pathogens 
like MRSA.  
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CHAPTER VI 
 
EFFORTS TOWARD DETERMINING THE SUBSTRATE SELECTIVITY OF BshC, AN 
ENZYME REQUIRED FOR BACILLITHIOL BIOSYNTHESIS4 
 
Results 
Crystal Structure Determination of BshC 
 Dr. Paul Cook’s lab at Grand Valley State University determined the first high resolution 
crystal structure of BshC from B. subtilis, which is the putative cysteine ligase in BSH biosynthesis 
(see Figure 8 – Chapter 1).20  The overall crystal structure had a final resolution of 1.77 Å and 
overall R factor of 17.0% (Figure 44).  Crystals in this study were grown in the presence of 200 
mM citrate and electron density corresponding to a citrate molecule was observed in the canonical 
Rossmann fold active site.  This 5- and 6- carboxylate groups of the citrate molecule likely mimic 
the 4- and 1-carboxylate groups, respectively, of the malyl moiety of glucosaminyl-malate and 
BSH, which means this provides clues as to how BshC accommodates that part of the substrate 
and product.   
Additionally, an adenosine diphosphate (ADP) molecule is bound within a pocket distinct 
from the canonical active site even though no nucleotides were added during the purification, 
dialysis, or crystallization of BshC.  Thus, this ligand came along with the protein when it was 
expressed in E. coli cells.  The electron densities of the adenine, ribose, and α-phosphate portions 
                                                        
4 Reprinted with permission from VanDuinen, A. J., Winchell, K. R., Keithly, M. E., and Cook, 
P. D. (2015) X-ray crystallographic structure of BshC, a unique enzyme involved in 
bacillithiol biosynthesis, Biochemistry 54 100-103. Copyright 2015 American Chemical 
Society, 
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of ADP are well-defined, but the density for the β-phosphoryl group is somewhat ambiguous, 
which indicates that a group other than phosphate is present at this position (Figure 45).  In an 
effort to identify this substrate, Dr. Cook sent samples of purified protein to our lab for analysis 
by LC-MS.1 
 
 
LC-MS Analysis of Purified BshC 
The native BshC enzyme was characterized for the presence of tightly-bound ligands using 
LC-MS analysis.  LC-MS of the protein in positive ionization mode was completed to determine 
 
Figure 44. Overall quaternary crystal structure of BshC at 1.77 Å with a citrate and ADP 
molecule bound to each monomer of the homodimer.   
 
Figure 45. BshC ADP ligand electron density.  Stereo view of electron density corresponding 
to the ADP molecule present in the second binding site.  The omit map shown was calculated 
from Fo-Fc and is contoured at 3σ. 
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the mass of the overall protein.  In order to calculate the mass, the charge state of the protein was 
determined using Equation 4 and then the mass was calculated from Equation 5. 
 
Equation 4: 𝑍2 =
𝑚1
𝑧1
−𝐻
𝑚2
𝑧2
−
𝑚1
𝑧1
  Equation 5: 𝑀 = 𝑍2(
𝑚2
𝑧2
− 𝐻) 
 
The spectra revealed 2 peaks for each charge state in the centroid envelope of the protein 
(Figure 46).  The mass for each peak set was calculated and two average masses were determined.  
One mass corresponded to the molecular weight of the purified BshC and the second mass was 
approximately 200 Da higher.  This indicates that we have two distinct protein states, which 
correlate to the apo protein and substrate bound protein.  Additionally, this points to a tightly-
bound ligand, which we attempted to identify utilizing LC-MS/MS analysis in negative ionization 
mode. 
Spectra from LC-MS/MS analysis in negative mode revealed four abundant peaks with m/z 
of 112.72, 156.72, 262.72, and 425.72 (Figure 47).  A peak search conducted at MassBank was 
used to help in identifying these four peaks.45  The peak at 112.72 is found in adenosine 
triphosphate (ATP).  The peak at 156.72 is found in ADP.  The peak at 425.72 correlates to a peak 
found in ADP and ATP, typically at an m/z of approximately 426.1.  The last peak at 262.72 had 
no match in the database.  These data suggest that adenosine nucleosides are present in the sample, 
but their exact identity could not be confirmed. 
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Figure 46. LC-MS analysis of BshC in positive ionization mode. (A) Full spectra of showing the centroid for BshC.  (B) Zoom in on 
the centroid showing the two distinct peaks for the protein. 
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Figure 47. LC-MS spectrum of BshC ligands in negative ionization mode.  
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Discussion 
The proposed biosynthesis of BSH is a three step enzymatic process catalyzed by the 
glycosyltransferase BshA, the deacetylase BshB, and the putative cysteine ligase BshC.20  The 
activities of BshA and BshB have been confirmed via in vitro assays, but the activity of BshC has 
yet to be elucidated.  This work represents the first high resolution crystal structure of BshC and 
has provided insight into possible substrate identification for BshC. The overall crystal structure 
of BshC (Figure 44) had a citrate bound in the active site, which likely binds to the location for the 
malyl moiety of the glucosaminyl-malate and BSH substrates.  Additionally there is an ADP-like 
molecule bound in a distinct pocket separate from the active site.  Mass spectroscopic analysis of 
the protein suggests the presence of an adenosine nucleoside, but it could not provide unequivocal 
identification of the ligand. 
Cysteine-tRNA ligases and the MSH cysteine ligase, MshC, add cysteine to an acceptor 
molecule via a process that requires the activation of cysteine by ATP before attachment of the 
cysteine to the acceptor molecule.52  Given the similarities between MSH and BSH, we might 
expect the putative cysteine ligases to function in a similar matter, which could explain the 
presence of the ADP-like molecule bound in our crystal structure.  However, the ADP-binding 
pocket of BshC is not present in MshC or cysteine-tRNA ligases.  Therefore, the biological 
significance of the ADP molecule and the binding site that it occupies still remains a mystery.  It 
is possible that the binding pocket functions in regulation or serves as a second catalytic site.  
Further structural and functional analysis of BshC is warranted to investigate the role of ADP and 
this binding pocket. 
The proliferation of multi-drug resistant pathogens, such as MRSA, represents a growing 
threat to human health.  Investigation of the BSH biosynthesis pathway, including BshC, will 
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provide insight into new possible therapeutic targets to combat resistance to the antibiotic Fos.  
The new structure of BshC has provided insight into possible substrates necessary for activity of 
the enzyme.  Furthermore, this work provides a foundation for additional structure and functional 
studies of BshC. 
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CHAPTER VII 
 
CONCLUSIONS 
 
Summary 
 Microbial antibiotic resistance (MAR) was recognized shortly after the introduction of 
antibiotics to the clinical setting in the 1940’s.  Over the years, MAR has becoming a global threat 
that increases each year and has culminated in the emergence of multiple-drug resistant organisms.  
These infections are invulnerable to treatment with several antimicrobial agents.  With the 
discovery of new antibiotics decreasing each year, new methods of treatment for MAR infections 
are in dire need.   
One method to fight the rising tide of MAR infections is to make old, underutilized 
antibiotics more effective.2, 4, 7b, 7c  While the exact mechanism of MAR can vary, antibiotic 
modifying or destroying enzymes represent one of the most common modes of microbial survival.  
Combination therapies of administering antibiotics in conjunction with enzyme inhibitors has 
proven successful.  Augmentin combines penicillin, a β-lactam antibiotic, with β-lactamase 
inhibitors to successfully treat β-lactam resistant bacterial strains.   
Fos is a broad-spectrum antibiotic produced by strains of Streptomyces that has no 
significant side effects.8  It can be administered for the treatment of Gram-positive and Gram-
negative bacterial infections in a single three gram dose.8  Fos functions by inactivating the enzyme 
MurA, which inhibits bacterial cell wall biosynthesis.  MurA catalyzes the first committed step in 
peptidoglycan biosynthesis, which is a necessary building block for the bacterial cell wall.9  
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However, like all known antibiotics, Fos has known enzymatic antibiotic resistance in both Gram-
positive and Gram-negative organisms.   
There are three distinct classes of Fos resistance enzymes.  FosA is a Mn2+- and K+-
dependent GSH-transferase found in Gram-negative organisms that catalyzes the nucleophilic 
addition of GSH to carbon-1 of Fos.15  This opens the epoxide ring of Fos and resulting in a 
modified compound with no bactericidal properties.  FosX is a Mn2+-dependent hydrolase that 
catalyzes the hydration of Fos at carbon-1 forming a vicinal diol and inactivating Fos.16   
The third class, FosB, is found in Gram-positive organisms, such as S. aureus, B. subtilis, 
B. cereus, and B. anthracis.  Initial analysis of FosBBs categorized this enzyme as a Mg2+-
dependent L-cysteine-transferase, which catalyzes the nucleophilic addition of L-cysteine to 
carbon-1 of Fos in a reaction similar to that of FosA.17  However, the L-cysteine-transferase 
activity of FosBBs is poor (kcat/KM
thiol ~180 M-1s-1) compared to the GSH-transferase activity of 
FosA from P. aeruginosa (kcat/KM
thiol ~1.7 X 105 M-1s-1) and is not sufficient to confer the robust 
Fos resistance seen in vivo.17   
In 2009, a new LMW-thiol, BSH, was discovered in Gram-positive organisms in 
concentrations equal to that of L-cysteine.19  Studies of BSH null strains of B. subtilis indicated 
that these cells had an increased sensitivity to Fos compared to WT cells.20  Initial time course data 
completed by Sharma et al. comparing FosB activity with L-cysteine and BSH indicated that FosB 
prefers BSH over L-cysteine as a thiol substrate.22  These results prompted the work presented in 
this dissertation.  In an effort to better understand the catalytic mechanism and substrate selectivity 
of FosB, we completed kinetic analyses, structural studies, and in vivo experiments on FosB from 
multiple strains of Gram-positive bacteria. 
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The kinetic analyses indicate that FosB has a clear preference for BSH over L-cysteine.  A 
probe of divalent metal activation revealed the order of activation in vitro to be Mn2+ > Ni2+ > 
Mg2+ > Zn2+.46, 51, 53  Additionally, Zn2+ was shown to be a potent inhibitor of FosB BSH-
transferase and L-cysteine-transferase activity even when physiological relevant concentrations of 
Mn2+ were present.51, 53  Lastly, the disk diffusion assays completed in collaboration with Dr. Eric 
Skaar’s lab indicate that both FosB and BSH are necessary for strains of S. aureus to be resistant 
to Fos.53  Together, these data allowed us to categorize FosB as a Mn2+-dependent BSH-
transferase. 
We were able to determine a total of 14 high resolution structures of FosB, 9 from FosBBc 
and 5 from FosBSa.51, 53  These structures were determined with FosB in complex with various 
divalent metals, substrates, and products.  The overall structure confirmed that FosB belongs to 
the VOC superfamily of enzymes, similar to the other Fos resistance enzymes, FosA and FosX.  
FosB has the three-dimensional domain-swapped arrangement of sequential βαβββ motifs in 
which both subunits of the homodimer participate in coordination of the metal ion and formation 
of the active site, which defines the VOC superfamily.   
The structures from FosBBc revealed key structural features of FosB.  Analysis of Fos 
coordination to metal in the active site of FosBBc revealed a cage of amino acids that orients Fos 
for nucleophilic attack of the carbon-1 of Fos.51  The cage has both a polar end, which coordinates 
to the phosphonate group of Fos, and a non-polar end to coordinate the antibiotic in the active site.   
Additionally, surface analysis of the structure revealed a solvent access channel that leads 
directly to the centered carbon-1 of Fos.51  This solvent channel is large enough to accommodate 
either L-cysteine or the cysteine moiety of BSH.  At the opening of the solvent access channel, 
there is a binding pocket that is appropriate in size and shape to bind the glucosamine-malate 
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moiety of BSH.  Since the kinetic analyses indicate FosB has a preference for BSH over L-cysteine, 
this suggests that the glucosamine-malate moiety of BSH is important for substrate recognition.  
Therefore, this binding pocket may have a significant role in the achieving maximum catalytic 
activity of FosB. 
A comparison of the FosBBc structure in complex with Mn2+ and Fos (PDB 4JH6) to the 
apo FosBSa structure (PDB 4NB2) indicates that movement of the phosphonate binding loop region 
may be required for Fos binding in the active site of the enzyme.53  In the FosBBc complex structure, 
the loop is observed in the closed confirmation.  In contrast, the loop is in an open conformation 
on the apo FosBSa structure.  The loop, which is conserved in throughout the FosB enzymes, can 
be morphed from the open conformation into the closed conformation.  In addition, the size of the 
solvent access channel at its most narrow point is not large enough to accommodate Fos.  Together 
these data suggest that the loop region must open to allow Fos to have access to the active site.  
In an effort to probe the dynamic movement of the phosphonate binding loop region, HDX-
MS analyses were completed with FosBSa.  The overall low incorporation of deuterium indicate 
that FosB is a relatively stable protein with little dynamic movement.  While peptide mapping 
provided 97 % coverage of FosBSa with multiple overlapping peptides to represent the phosphonate 
binding loop region, the signal for these peptides was lost when the separation gradient was 
changed for HDX-MS analysis.  Therefore, we were unable to determine any dynamic movement 
of the phosphonate binding loop using this method. 
Finally, we worked in collaboration with Dr. Paul Cook to interrogate the substrate 
selectivity of BshC, an enzyme necessary for BSH biosynthesis.  Since BSH is necessary for 
maximum FosB activity, the biosynthetic pathway for BSH could also be a therapeutic target for 
the development of inhibitors to combat Fos resistance.  Dr. Cook determined the first high 
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resolution crystal structure of BshC in complex with an ADP-like molecule and a citrate 
molecule.54  Since no nucleosides were introduced during purification or crystallization, we 
completed LC-MS analysis of the purified protein to probe the identity of the ADP-like ligand.  
The analysis indicates the presence of an adenosine nucleoside, but unequivocal identification of 
the ligand was not possible from our data. 
 
Significance and Impact 
 MAR is a major health threat on the rise and new methods to treat MAR infections must 
be found.  Fos alone and in combination with other antibiotics has recently been used to treat MAR 
infections in the clinical setting.11a, 11b, 55  However, the presence of Fos resistance enzymes 
decreases the efficacy of the antibiotic in the clinical setting.  Since Fos is a broad spectrum 
antibiotic with very few side effects, it would be beneficial to find a way to improve the efficacy 
of the antibiotic for use in treating MAR infections.   
 The ability for Fos to treat both Gram-positive and Gram-negative infections make this 
drug an attractive therapeutic for MAR infections.  This work has determined the structure and 
mechanism of catalytic activity for a variety of FosB enzymes, which are found in Gram-positive 
bacteria.  FosA, found in Gram-negative organisms, has previously been studied.  The data from 
this dissertation combined with the FosA data can be used by drug companies to design inhibitors 
of the Fos resistance enzymes.  The method of combining a resistance enzyme inhibitor with an 
antibiotic has previously been successful.  An inhibitor of Fos resistance enzymes in combination 
with Fos would increase the efficacy of the antibiotic and make it a more viable treatment for MAR 
infections. 
 
 107 
Future Work 
 The work presented in this dissertation establishes the in vitro substrate selectivity and the 
order of divalent metal activation for the FosB enzymes.  The structural studies provide insight 
into the catalytic mechanism of FosB.  This information could provide crucial details to developing 
FosB inhibitors that could be given in conjunction with Fos to increase the efficacy of the antibiotic 
in the clinical setting.  However, additional analysis is warranted to confirm in vivo activity of 
FosB and to further probe the structural features identified here. 
 While we did determine 14 high resolution structures of FosB in complex with various 
divalent metals, substrates, and/or product, we have not yet been successful in determining a 
crystal structure with the full molecule of BSH or BS-Fos present, which is necessary for any 
future structure based inhibitor development.  Also, our attempts to probe the dynamic movement 
of the phosphonate binding loop region using HDX-MS were unsuccessful.  Therefore, we have 
initiated NMR analysis of FosBSa in order to probe the dynamic movement of the loop region and 
interrogate the location of BSH binding. 
 The rapid spread of multi-drug resistant infections, such as MRSA, represents a growing 
global threat to human health.  In order to combat this rising threat, we must continue to develop 
alternative therapies for treatment.  Fos represents a promising antibiotic that could be used to treat 
these types of infections, but the prevalence of enzymatic resistance to Fos decreases the efficacy 
of the antibiotic in the clinical setting.  Therefore, the development of drugs that can inhibit this 
resistance pathway can be used in combination with Fos in order to improve the efficacy of the 
antibiotic. A better understanding of both FosB in vivo activity and the BSH biosynthesis pathway 
can provide the information required for designing these novel inhibitors. 
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APPENDIX A 
 
STRUCTURE DETERMINATION OF THE BS-Fos PRODUCT FORMED BY THE FosB 
ENZYME FOUND IN Staphylococcus saprophyticus 
 
Preliminary Results 
 As previously described, a 31P NMR assay can be utilized to determine the time course 
kinetic profile of the FosB enzymes based upon the amount of product formed over time.   This 
assay requires the use of peak height ratios of Fos and the product with the law of conservation of 
mass to determine the amount of product formed.  FosBSa, FosBBc, FosBBs, and FosBBa catalyze 
the nucleophilic addition of both L-cysteine and BSH to Fos producing a unique singlet peak for 
each product. 
 During the course of this work, I also assayed the reaction catalyzed by FosB from 
Staphylococcus saprophyticus (FosBSs).  As expected, FosBSs catalyzed the nucleophilic addition 
of L-cysteine to Fos producing a singlet peak on the 31P NMR spectra.  However, the FosBSs 
reaction with BSH present, produces two peaks (Figure 48).  One possible explanation is that the 
two peaks represent stereo or region isomers of the BS-Fos product.   
 I was unsuccessful in isolating these two products from the reaction.  However, future work 
should investigate the identity of these two products.  Since BSH is believed to be the in vivo 
substrate for the FosB enzymes, it is imperative to understand why this Gram-positive bacterium 
produces a different product than other known Gram-positive bacteria.  Additionally, insight into 
the structure of FosBSs compared to the structures determined for FosBBc and FosBSa will provide 
further details into the differences between these enzymes.  Combined, this information could be 
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used to better design inhibitors of FosB enzymes from multiple organisms and ultimately increase 
the efficacy of the antibiotic in the clinical setting. 
 
  
 
Figure 48. NMR spectrum of the double peak formed by the FosBSs catalyzed nucleophilic addition of 
bacillithiol to fosfomycin. 
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APPENDIX B 
 
THE INVESTIGATION OF INHIBITION OF THE FosB ENZYMES BY N-acetylglucosamine-
malate, AN INTERMEDIATE OF THE BACILLITHIOL BIOSYNTHESIS PATHWAY 
 
Preliminary Results 
 FosB enzymes catalyze the nucleophilic addition of BSH to the antibiotic Fos, which 
modifies Fos making it ineffective.  The BSH biosynthesis pathway (see Figure 6 – Chapter 1) 
produces GlcNAc-Mal as an intermediate.  GlcNAc-Mal is a truncated version of BSH that has an 
acetyl group in place of the cysteine moiety (Figure 49).  It cannot perform the nucleophilic attack 
necessary to inactivate Fos.  However, it is possible that it could still bind to the active site of FosB 
and act as an inhibitor of the enzyme.   
 
 
Figure 49. Comparison of the GlcNAc-Mal and BSH structures.  GlcNAc-Mal (left), an 
intermediate in the BSH biosynthesis pathway, is a truncated version of BSH, which contains an 
acetyl group in place of the cysteine moiety. 
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 Preliminary NMR assays indicate that GlcNAc-Mal is able to inhibit the FosBBs catalyzed 
nucleophilic addition of L-cysteine to Fos (Figure 50).   After 10 minutes, the reaction catalyzed 
in the presence of Glc-NAc-Mal has significantly less product formed than the reaction without 
Glc-NAc-Mal present.  After 30 minutes, additional product formation is seen in the reaction 
catalyzed in the presence of Glc-NAc-Mal, but the reaction still has not run to completion.  This 
indicates that Glc-NAc-Mal acts as an inhibitor of FosB, but it is not complete inhibition.   
 
  
Further analysis, including complete inhibitor kinetic studies, of the FosB catalyzed 
addition of both L-cysteine and BSH to Fos should be completed.  Additionally, crystallography 
 
 
Figure 50. NMR spectra of the FosB catalyzed nucleophilic addition to L-cysteine to Fos at 10 and 
30 minutes. Reactions were carried out at 25˚ C in 20 mM HEPES, pH 7.0 with 4.8 mM fosfomycin, 
2.4 mM L-cysteine, and 0.8 mM enzyme in the (A) and (C) absence or (B) and (D) presence of 
2.22 mM GlcNAc-Mal. 
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studies would provide valuable information regarding the mode of inhibition.  These data could 
assist in designing inhibitors of the FosB enzymes to increase the efficacy of Fos.  Furthermore, 
this could indicate that inhibition of BshC increasing Glc-NAc-Mal production would also be a 
valid pathway to increase Fos efficacy in vivo. 
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TEACHING EXPERIENCE 
Vanderbilt University Center for Science Outreach September 2012- May 2016 
Science Teaching Fellow (STF), 7th Grade Science, Rose Park Middle School 
  June 2013-May 2016 
 Co-taught planned lessons one day per week to ~100 students with a variety of 
backgrounds and abilities. 
 Designed lesson plans and assignments for 7th grade science course in partnership with 
the teacher. 
 Led a presentation and lab activity on my research. 
STF, Interdisciplinary Science Research , Hillsboro High School September 2012-May 2013 
 Assisted with teaching and helping students in 4 ISR courses and 1 Chemistry Course, 
which includes ~80 students with a variety of backgrounds and abilities. 
 Designed lab lesson plans and assignments for Chemistry Course also taught by ISR 
instructor. 
 Graded chemistry assignments that I prepared. 
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Vanderbilt University Center for Teaching May 2014-December 2015 
BOLD Fellow (Teaching as Research Project), Principles of Genetics  
 Developed 3 web modules for 3 topics to be implemented as a flipped classroom in 
conjunction with two professors. 
 Assisted 2 professors in implementing the flipped classroom for 4 class sessions in 
genetics. 
 Developed and administer pre-/post-tests, satisfaction surveys, and classroom 
observations to assess the implementation of the flipped classroom. 
 Obtain IRB approval for the research project. 
 Data showed no specific learning gains when comparing pre-/post-test scores between 
traditional lecture and a blended class design, but did provide evidence of higher 
cognitive activity (as categorized by Bloom’s Taxonomy) during class time when using 
a blended classroom approach. 
 Student satisfaction surveys indicate that the majority of students like the blended 
classroom and find it more effective than traditional lecture. 
 A description of the project and the results can be found at 
http://vanderbilt.edu/bold/docs/bsci-2210-principles-of-genetics/ 
 
Vanderbilt University Center for Teaching August 2013-May 2015 
Graduate Teaching Affiliate   
 Attended a two week workshop covering how students learn, leading discussions, 
effective lecturing and information new teaching assistants (TA’s) need in order to 
prepare for teaching assistant orientation (TAO). 
 Led a full day TAO workshop for incoming Chemistry TA’s, which included 
approximately 20 students and for incoming engineering TA’s, which included 
approximately 20 students. 
 Prepared and co-led a one hour workshop at GradSTEP (Title:  Interactive Lecturing in 
Large Classrooms) for approximately 20 Vanderbilt graduate students, post-docs, or 
faculty. 
 Designed, filmed, and edited videos on what faculty expect of new TA’s in the 
Chemistry and Biological Sciences Department. 
 
Vanderbilt University Department of Biological Sciences April 2015 
Guest Lecturer, Biochemistry    
 Taught 2 lectures on amino acid catabolism. 
 Developed a lesson plan with guided worksheets to implement an interactive class 
lecture. 
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Vanderbilt University Department of Chemistry August 2010-April 2015 
Graduate Teaching Assistant, Organic Chemistry Stockroom            Spring 2015 
 Prepared and setup labs for Organic Chemistry II. 
 Maintained inventory of stockroom. 
 Cleaned stockroom and labs. 
Graduate Teaching Assistant, General Chemistry Recitation              Fall 2014 
 Taught 6 recitation sections to 150 chemistry students of a variety of backgrounds and 
abilities. 
 Created, administered, and graded quizzes.  
 Graded exams for General Chemistry lecture. 
Graduate Teaching Assistant, General Chemistry I Laboratory Fall, Spring 2010-2011 
 Taught lab to 48 chemistry students of a variety of backgrounds and abilities. 
 Proctored exams for General Chemistry Lecture. 
 Graded exams and lab reports. 
 
University of Missouri – St. Louis Disabilities Access Services August 2009-May 2010 
Tutor, Physical Chemistry I and II   
 Tutor one student with disabilities in Physical Chemistry I and II 
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Vanderbilt University Department of Chemistry June 2010-August 2016 
Graduate Research Fellow           
Advisor:  Richard N. Armstrong, Ph.D. (Deceased June 2015) 
Charles R. Sanders, Ph.D. and Walter J. Chazin, Ph.D. 
Topic: Structure, substrate selectivity, and catalytic mechanism of the fosfomycin 
resistance enzyme, FosB, from Gram-positive pathogens. 
 
University of Missouri – St. Louis Department of Chemistry January 2009-May 2010  
Undergraduate Researcher           
Advisor:  Cynthia Dupureur, Ph.D.  
Topic: The effect of phosphorylation on the conformation of hormone-sensitive 
lipase.  
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Vanderbilt University  August 2013-May 2014  
Conference Organizer, Biomolecular Structure, Dynamic, Function:  Membrane Protein  
 Student member of organizing committee for the conference. 
 Assisted in inviting and choosing speakers. 
 Assisted in planning all sessions of the conference. 
 Planned the conference dinner for attendees at the Bound’ry restaurant. 
 Served as a session chair for one session. 
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 Shen J, Keithly ME, Armstrong RN, Higgins KA, Edminds KA, Giedroc DP  
Staphylococcus aureus CstB is a Novel Multidomain Persulfide Dioxygenase-
Sulfurtransferase Involved in Hydrogen Sulfide Detoxification. Biochemistry. (2015) 54, 
4542-54 
 Vanduinen AJ, Winchell KR, Keithly ME, Cook PD X-ray crystallographic structure of 
BshC, a unique enzyme involved in bacillithiol biosynthesis. Biochemistry. (2015) 54, 
100-103 
 Thompson MK, Keithly ME, Sulikowski GA, Armstrong RN, Diversity in fosfomycin 
resistance proteins. Perspect. Sci. (2015) 4, 17-23. 
 Thompson MK, Keithly ME,  Goodman MC, Hammer ND, Cook PD, Jagessar KL, Harp 
J, Skaar EP, Armstrong RN, Structure and Function of the Genomically Encoded 
Fosfomycin Resistance Enzyme, FosB, from Staphylococcus aureus.  Biochemistry. 
(2014) 53, 755-765. 
Highlighted in the 58th Annual Biophysical Society National Meeting Press Release. 
 Thompson MK, Keithly ME, Harp J, Cook PD, Jagessar KL, Sulikowski GA, Armstrong 
RN, Structural and Chemical Aspects of Resistance to the Antibiotic Fosfomycin 
Conferred by FosB from Bacillus cereus. Biochemistry. (2013) 52, 7350-62. 
 Lamers AP, Keithly ME, Kim K, Cook PD, Stec DF, Hines KM, Sulikowski GA, 
Armstrong RN, Synthesis of Bacillithiol and the Catalytic Selectivity of FosB-type 
Fosfomycin Resistance Proteins.  Org. Lett. (2012) 14, 5207-9. 
 
PEER REVIEWED PRESENTATIONS 
Oral presentation National Science Teacher Association’s National Conference April 2016
 Music City Center, Nashville, TN 
  Title: How To Master Scientists Inside The Classroom With High Results. 
 
Oral presentation American Chemical Society SERMACS-SWRM Conference November 2015
 Memphis-Cook Convention Center, Memphis, TN 
Title: Investigating enzymatic resistance to fosfomycin by FosB in Gram-
positive bacteria 
 
Poster presenter  The 35th Midwest Enzyme Chemistry Conference  September 2015 
Illinois Institute of Technology, Chicago, IL 
Title: Investigating enzymatic resistance to fosfomycin by FosB in Gram-
positive bacteria. 
 
Poster presenter  American Chemical Society National Meeting  August 2015 
Boston Convention & Exhibition Center, Boston, MA 
Title: Investigating enzymatic resistance to fosfomycin by FosB in Gram-
positive bacteria. 
Title: Blending it up:  Active learning in a STEM classroom through the use 
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Poster presenter Biomolecular Structure, Dynamic, Function:  Membrane Protein May 2014  
Vanderbilt University, Nashville, TN 
Title: Interrogation of 5–lipoxygenase activating protein 
interactions with substrate, inhibitor, and during protein complex 
formation via Hydrogen-Deuterium exchange mass spectrometry. 
 
Poster presenter 58th Annual Biophysical Society National Meeting February 2014  
Moscone Convention Center, San Francisco, CA 
Title: Substrate and Metal Ion Specificity of Fosfomycin Resistance 
Protein, FosB. 
 
Poster presenter 2013 ASBMB Career Symposium September 2013  
University of Missouri, Columbia, MO 
Title: Vanderbilt Center for Science Outreach 
 
Poster presenter VICB Tenth Anniversary Symposium    March 2013  
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Title: Investigation of Substrate and Metal Ion Selectivity of the 
Fosfomycin Resistance Protein, FosB. 
 
Poster presenter 23rd Enzyme Mechanisms Conference    January 2013  
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Title: Investigation of Substrate and Metal Ion Selectivity of the 
Fosfomycin Resistance Protein, FosB. 
 
Poster presenter Vanderbilt Institute of Chemical Biology Student Symposium August 2012  
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Title: Structural and Functional Investigation of the Fosfomycin 
Resistance Protein, FosB.  
 
Poster presenter  American Chemical Society National Meeting       March 2010 
San Francisco, California  
Title: The effect of phosphorylation on the conformation of hormone-
sensitive lipase. 
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Oral presentation Center in Molecular Toxicology Enzymology Meeting February 2015
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Title: Elucidating the Mechanism of the Fosfomycin Resistance Protein, 
FosB. 
 
Oral presentation Center in Molecular Toxicology Enzymology Meeting May 2014
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Title: Investigation of Substrate and Metal Ion Selectivity of the 
Fosfomycin Resistance Protein, FosB. 
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mutagenesis 
 Recombinant protein expression in Escherichia coli  
 Protein purification 
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 Molecular graphics including Pymol and Chimera 
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 HPLC, GC, Titrations 
 
Volunteer Intern Microbe Inotech Laboratories July 2008-May 2009 
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 Completed accurate daily counts for multiple tests including TPC, TC, SAB, Yeast & Mold 
counts, Fungi counts. 
 Ran tests for strain identification including BioLog and Vytek identification 
 Tested for E. Coli, Salmonella, Listeria, and Staph using Vidas and set up tests for plate 
counts. 
 Received samples and maintained files with accurate information for reporting to clients. 
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 American Institute of Chemists – Student Award Certificate (2010) 
 Certificate of Commendation for Outstanding Service (2010) 
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